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1 List of abbreviations 
 
ACTH              Adrenocorticotropic hormone 
AGA  Androgenetic alopecia 
APM  Arrector pili muscle 
ATRA  All-trans retinoid acid 
BDNF  Brain-derived nerve growth factor 
BMP  Bone morphogenic protein 
CL  Club hair 
CK6  Cytokeratin 6 
CRH  Corticotrophin-releasing hormone 
CsA  Cyclosporin A 
CTS  Connective tissue sheath 
CTSL  Cathepsin L 
DAPI  4′,6-Diamidin-2-phenylindol fluorescent stain 
DMEM  Dulbecco’s modified Eagle’s medium 
DP  Dermal papilla 
DPC  Dermal papilla cells / fibroblasts 
E2  17-beta estradiol 
ER  Estrogen receptor 
FBS  Fetal bovine serum 
FC  Fetal clone 
FDA  Food and Drug Administration 
FGF-7  Fibroblast growth factor 7 
GDNF  Glial cell line-derived neurotrophic factor 
HaCaT  Human keratinocyte cell line 
HDF  Human dermal fibroblasts 
HE  Hematoxylin-eosin 
HF  Hair follicle 
HFM  Human folliculoid microspheres 
HGF  Hepatocyte growth factor 
HR  Hairless gene 
IFNy  Interferon gamma 
IGF-1  Insulin-like growth factor 1 
IL-1  Interleukin 1 
IRS  Inner root sheath 
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LEF-1  Lymphoid enhancer-binding protein 1 
LDH  Lactate-Dehydrogenase 
MSH               Melanocyte-stimulating hormone 
NCAM  Neural cell adhesion molecule 
NGF  Nerve growth factor 
NHEK  Normal human epidermal keratinocytes 
ORS  Outer root sheath 
ORSK  Outer root sheath keratinocytes 
P75NTR Low affinity neurotrophin receptor 
PBS  Phosphate-buffered saline 
PRL  Prolactin 
PRLR  Prolactin receptor 
RAR  Retinoid acid receptor 
RC  Rough coat 
RT- PCR Real-Time-quantitative Polymerase Chain Reaction 
RXR  Retinoid X receptor 
SCF  Stem cell factor 
SG  Sebaceous gland 
SHH  Sonic hedgehog 
STAT-3 Signal transducer and activator of transcription 3 
TGFβ  Transforming growth factor beta 
TNFα  Tumor necrosis factor alpha 
TSP-1  Thrombospondin 1 
TUNEL Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling  
VEGF  Vascular endothelial growth factor 
VR-1  Vanilloid receptor 1 
WNT  Wingless gene 
3D  Three-dimensional 
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2 Introduction  
 
The loss of scalp hair (effluvium, alopecia) can be accompanied by severe 
psychological problems in a vastly underestimated number of afflicted 
patients57.Therefore the development of ever-new and hopefully more effective 
drugs for the management of common hair growth disorders remains a top priority 
both for clinical dermatology and the industry143.  
Most hair growth disturbances seen in clinical practice primarily result from 
changes in hair follicle cycling. Thus, a more profound understanding of the mo-
lecular controls of hair follicle cycling and its underlying disturbances promises to 
lead to the development of more effective “hair drugs,” one of the prime challenges 
of modern hair research. 
  The search for such hair drugs is, however, severely handicapped by the 
lack of satisfactory three-dimensional (3D) in vitro screening systems that suffi-
ciently mimic important epithelial-mesenchymal interactions as they occur in hu-
man hair follicles (HF). Therefore, pragmatic 3D screening systems are urgently 
needed, as preservation of native epithelial-mesenchymal interactions is superior 
to simple co-culture assays for isolated HF cell populations in which these interac-
tions are disrupted103,178, and hence data produced with such cell culture studies 
reflect highly artificial conditions, provide very uncertain predictive value for the 
clinical situation, and are therefore inappropriate for the screening purposes dis-
cussed here. 
For pre-clinical R&D (research and development) purposes, a simplified 3D 
folliculoid systems should provide a first-line screening tool for large-scale in vitro 
testing, to be followed by organ culture of micro-dissected human anagen hair 
bulbs159 and histocultures of hair-bearing skin, i.e. micro-dissected normal 
skin97,98,110 for the most promising agents that have been identified in this manner 
as a second-line assay, and eventual clinical testing as the ultimate and only fully 
reliable test system. 
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The main aim of this study was therefore to develop a human tissue- 
engineered hair equivalents for investigative dermatology that provides well-
defined basic parameters for detailed exploration of epithelial-mesenchymal 
interactions in the human hair follicle. 
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3 Skin Equivalents 
 
3.1 Tissue Engineering 
 
Decades ago, the possibility of growing replacement tissues to repair hu-
man skin was considered science fiction. When substitution of the skin was re-
quired, the only options were split or full-thickness skin grafts, tissue flaps and 
free-tissue transfers166. Over the last 30 years, tissue-engineered skin equivalents 
has developed and progressed at a very rapid rate. Today, there are some tissue 
engineered skin equivalents approved for use by the US Food and Drug Admini-
stration (FDA) and many others undergoing testing and development. Tissue-
engineered skin substitutes offer tissue replacement without requiring a donor site 
and may produce better healing39. Tissue engineering was defined in 1987 by the 
National Science Foundation bioengineering panel meeting in Washington, DC, 
USA, as ‘the application of the principles and methods of engineering and the life 
sciences toward the development of biological substitutes to restore, maintain, or 
improve function46.  
 
Key materials for tissue engineering are cells, matrix material (scaffold) and 
growth factors. The cell synthesizes matrices of new tissue, while the scaffold pro-
vides the appropriate environment for cells to be able to effectively accomplish 
their missions. The function of growth factors is to facilitate and promote cells to 
regenerate new tissue73. Future directions include genetic modification of trans-
planted cells to improve wound healing transiently or to deliver gene products sys-
temically17.  
A short review of some engineered skin equivalents are listed here. 
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3.2 Human Tissue- Engineered Skin Equivalents commercially available 
 
3.2.1 Cultured Epidermal Autografts (Epicel™) 
 
In 1975, Rheinwald and Green developed a technique that permitted epi-
dermal keratinocytes to be cultured in vitro using a feeder layer of irradiated mur-
ine fibroblasts177. From a skin biopsy, dermis and subcutaneous tissue were re-
moved, epidermis was minced and trypsinized, and a cell suspension was seeded 
on lethally irradiated 3T3 mouse fibroblasts (which can not multiply and inhibit 
growth of human fibroblasts from the biopsy). The standard culture medium was 
enriched by cholera toxin, epidermal growth factor, adenosine, insulin and hydro-
cortisone56,177. Small colonies formed within days after a cell suspension was 
plated. When cultures reached confluence, the keratinocytes were released with 
dispase and attached to a non-adherent gauze dressing56. Two to three weeks 
were required before the cultured graft was available. Using this technique, cul-
tured epidermal autografts (Epicel™), were first produced in 1988. The advan-
tages of cultured epidermal autografts are the potential provision of permanent 
wound coverage66,132, a decreased requirement for donor sites, pain relief, and a 
better functional and cosmetic outcome. The disadvantages are the requirement 
for a skin biopsy (or biopsies), a 3-week delay for graft cultivation, the lack of a 
dermal component, and high costs. Cultured epidermal autografts have been used 
to treat burns54,132, chronic leg ulcers66, epidermolysis bullosa23, cutaneous 
wounds resulting from excision of giant congenital nevi55, vitiligo164, chronic mas-
toiditis169, congenital hypospadias179, pressure ulcers157, and corneal replace-
ment150. However, cultured epidermal autografts are not a complete bi-layered 
skin, and the scar contraction and unstable attachment to the wound bed is attrib-
uted to the absence of a dermal substrate58.  
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3.2.2 Cultured Epidermal Allografts 
 
Cultured epidermal allografts are derived from unrelated allogeneic donors, 
such as newborn foreskin, can be grown in advance and may be stockpiled. They 
promote granulation formation and stimulate epithelialization from wound edges 
and from adnexal structures in the dermal bed of superficial wounds, probably 
through growth factor release154. The advantage of using cultured epidermal al-
lografts is immediate graft availability. The disadvantages are that they do not sur-
vive permanently on the wound bed, and there is a possibility of disease transmis-
sion, which can be minimized with an extensive screening. Cultured epidermal al-
lografts have been used to treat burns34,72,67,114, chronic leg ulcers37,96,155,156, donor 
sites158, and epidermolysis bullosa118. Cultured epidermal allografts can be cryo-
preserved and stored at –70°C to –120°C and thawed at room temperature before 
using12.  
 
3.2.3  Non-living Allogeneic Acellular Dermal Matrix (Alloderm®) 
 
Alloderm® is an acellular matrix material, processed directly from fresh ca-
daver skin that is treated with high salt to remove the epidermis and extracted with 
a solution to remove the cellular material. It is then freeze dried, leaving an immu-
nologically inert acellular dermal matrix with intact basement membrane complex. 
It has been used to treat burns since 1992. It can be glycerol preserved or lyophi-
lized. The advantages of this dermal matrix include: it is acellular and immunologi-
cally inert; it provides a template with natural dermal porosity for regeneration with 
the presence of an intact basement membrane; and it allows the use of thinner 
autografts. The disadvantages include risk of transmitting infectious diseases203.  
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3.2.4 Non-living Extracellular Matrix of Collagen and Chondroitin-6-Sulfate 
(Integra®) 
 
An in vitro dermal replacement, Integra® is an artificial skin developed by 
Burke and Yannas22. It consists of an artificial dermis (matrix of bovine collagen 
and chondroitin-6-sulfate, a shark-derived glycosaminoglycan) and a disposable 
silicone sheet (artificial epidermis). The matrix becomes vascularized, then the 
disposable epidermis is removed and can be replaced with a split thickness skin 
graft. In 1996, the FDA approved its use in burns. The advantage of using this arti-
ficial dermis is that it allows a neo-dermis to develop. The disadvantages are the 
collection of fluid under Integra® with the possibility of unnoticed infection, and the 
lack of a real epidermal component20.   
 
3.2.5 Cultured Skin Substitute 
 
A collagen and glycosaminoglycan dermal skin substitute was studied as 
substrate for cultured human epidermal keratinocytes18. Hansbrough61 further de-
veloped this skin substitute, which is prepared in vitro and transferred as a unit to 
the wound bed. This skin substitute is composed of autologous cultured keratino-
cytes as the epidermal component, and collagen and glycosaminoglycan substrate 
inoculated with autologous fibroblasts as the dermal component. Formation of rete 
ridge interdigitation, and basement membranes proteins (laminin and type IV col-
lagen), were identified immunohistochemically.The disadvantage of this skin sub-
stitute is the need to wait 3 to 4 weeks to produce the cultured grafts. Later 
Boyce21 added human melanocytes to the skin culture composed of human epi-
dermal keratinocytes, dermal fibroblasts and collagen glycosaminoglycan sub-
strates, and demonstrated restoration of pigmentation and inhibition of wound con-
traction after transplantation to athymic mice. More studies are needed to deter-
mine the effectiveness of this composite skin substitute.  
 
 
 
 
 
   Hair Equivalents
 
 Page 14 of 107 
 
3.2.6 Living Allogeneic Dermal Fibroblasts (Dermagraft®) 
 
A living dermal replacement (Dermagraft®) can be obtained by culturing 
human neonatal fibroblasts on a polyglyactin mesh. This method was developed 
by Cooper26. Dermal fibroblasts from neonatal foreskin are seeded on a bioab-
sorbable mesh, in a sterile bag with circulating nutrients. These cells attach, multi-
ply and begin secreting collagens and growth factors. The cells and the collagen 
proteins form a solid tissue by covering the mesh inside and outside. The mesh is 
made of biodegradable material and disappears after 3 to 4 weeks. This fibroblast 
collagen matrix can be used alone or as a base for meshed autografts or possible 
epidermal cultures154. The advantages of this skin substitute include good resis-
tance to tearing, ease of handling, and lack of rejection60,165. 
  
3.2.7 Extracellular Matrix of Allogeneic Human Dermal Fibroblasts          
(Transcyte™) 
 
Transcyte™ is a laboratory-grown temporary skin replacement. Neonatal 
(allogeneic) fibroblasts are cultured and proliferate on nylon fibers that are embed-
ded into a silastic layer for 4 to 6 weeks, forming a dense cellular ‘tissue’ which 
contains high levels of secreted human matrix proteins as well as multiple growth 
factors60. The fibroblasts are rendered non-viable by freezing after synthesizing 
collagen extracellular matrix and growth factors. TransCyte™ is approved for the 
treatment of burn wounds, and advantages include immediate availability and easy 
storage171.  
 
3.2.8 Living Allogeneic Bilayered Skin Construct (Apligraf®) 
 
A living human skin equivalent was first developed by Bell et al7. Apligraf® 
(also known as ‘Graftskin’) is a bilayered skin construct or living human skin 
equivalent, composed of living keratinocytes and dermal fibroblasts, derived from 
neonatal foreskin and propagated in culture. Initially, dermal fibroblasts are com-
bined with type I bovine collagen. Subsequently, keratinocytes overlying the epi-
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dermis are exposed to an air-liquid interface to promote formation of a stratum 
corneum208. Apligraf® resembles human skin histologically, produces matrix pro-
teins and growth factors, and can heal itself, following an injury45. Apligraf® gained 
FDA approval for the treatment of venous ulcers based on its efficacy in a con-
trolled, randomized, multicenter study performed in 293 patients with venous ul-
cers. It has also been used to treat patients with epidermolysis bullosa43,44 and in 
acute, partial or full-thickness excisional wounds made mostly by excision of skin 
cancer38. The advantages of using Apligraf® include ease of application, ability to 
apply the graft as an outpatient procedure, and avoidance of a surgical procedure 
that leaves a donor site wound. The disadvantages are its short shelf life (5 days) 
and cost. 
 
3.2.9 Composite Cultured Skin (OrCel™) 
 
Another living skin equivalent is the composite cultured skin, which consists 
of allogeneic fibroblasts and keratinocytes grown in vitro and seeded on opposite 
sides of a bilayered matrix of bovine collagen129. The collagen matrix consists of a 
cross-linked bovine collagen sponge coated with an overlay of pepsinized insolu-
ble collagen. Keratinocytes are seeded over a non-porous collagen gel (insoluble 
collagen) and the fibroblasts are seeded on the underside of the porous sponge. 
They are cultured between 10 to 15 days. Composite cultured skin has been used 
as a partial substitution for autografts on digits and over donor sites in the course 
of 16 operations performed on 7 children with recessive dystrophic epidermolysis 
bullosa, syndactyly and flexor contracture of the fingers41. The advantage of this 
skin substitute is its immediate availability; the disadvantage is the little clinical 
data to support its use.  
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3.3 Tissue-Engineered Hair Equivalents 
 
3.3.1 Hair equivalents for wound healing 
 
An autologous epidermal equivalent generated in vitro from the patient’s 
hair (the outer root sheath cells of the hair follicle [ORSK]) has been grafted suc-
cessfully in a pilot study performed on 11 chronic leg ulcers105. The advantages of 
this graft include the easy isolation of precursor cells for epidermal keratinocytes 
from plucked scalp hair follicles and that these precursor cells retain a high prolif-
erative capacity irrespective of the age of the hair follicle donor. This epidermal 
equivalent is commercially available in Europe, as EpiDex™. 
 
3.3.2 Neogenesis of the hair follicle 
 
 
Many approaches for neogenesis of the hair follicle (creation hair follicle de 
novo) have been tested recently, e.g. autologous dermal cells from dissociated 
hair follicle expanded in the culture and then in combination with competent 
epithelial cells re-implanted to the scalp or forming hair follicle as mini organs in vi-
tro and then transplanting the newly generated follicles back to the alopetic 
scalp194. However, due to tissue engineering challenges the creation of new hair 
follicles for the treatment of alopecia has not been achieved yet. 
 
3.3.3 Hair equivalents for investigative dermatology 
 
Many different 3D organotypic assay systems based on human skin and 
hair cell populations have been developed for investigative dermatol-
ogy5,101,104,193,211. These systems allow so far limited study of the function of diffus-
ible factors affecting epithelial–mesenchymal interactions, the dynamics of base-
ment membrane formation and the testing of the effects of various modulators, 
growth hormones, nutrients, etc.112,113,188-190.The human skin equivalents have be-
come an indispensable alternative to animal models in pharmacological and toxi-
cological in vitro testing167. 
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Historically, normal human epidermal keratinocytes (NHEK) were first used 
in organotypic 3D systems112,189,190,193 and later ORSK were also employed 
101,102,104). In these systems cells were layered above collagen I, or collagen I 
mixed with human dermal fibroblasts (HDF), generating 'pseudodermis' 193. Later, 
these collagen I gels or a pseudodermis were covered with various cell and matrix 
mixtures, which contained basement membrane and extracellular matrix compo-
nents (MatrigelTM basement membrane matrix;), NHEK or ORSK, plus mesenchy-
mal cells (HDF or DPC) in a number of different designs101,193. Ultimately, in previ-
ously reported 3D systems, comprehensive data on the ratio of prolifera-
tion/apoptosis of ORSK and DPC and/or on HF-like differentiation markers have 
not been assessed in the classical studies that have pioneered the 
field101,113,188,189,193. 
A human tissue-engineered skin equivalent in for the investigation of trans-
follicular penetration has been developed by Michel125. It is produced from human 
fibroblasts and keratinocytes obtained from healthy adult skin specimens removed 
during reductive breast surgery, and does not contain any synthetic material. Pre-
viously extracted pilosebaceous units are then inserted in the dermal equivalent in 
which small holes have been previously made. The product has histological, im-
munological, immunohistological, and ultrastructural properties similar to healthy 
human skin. This new in vitro hair model could be used to further broaden the un-
derstanding of the transfollicular route in the transcutaneous delivery of active 
substances. 
 
In order to overcome numerous challenges, further progress needs to be 
made in understanding the molecular pathways activated during hair follicle em-
bryogenesis and hair cycling. Eventually, this understanding should lead to the 
generation of new pharmaceutical agents that specifically target these path-
ways194. 
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4 The Biology of the hair follicle 
4.1 Human hair follicles 
The hair follicle is one of the most complex mini-organs of the human body. 
This exquisitely productive protein fiber factory, which doubles as a sensory organ 
and serves as an instrument of psychosocial communication, excretion, and pro-
tection, undergoes cyclic transformations between phases of rapid growth (ana-
gen), apoptosis-driven regression (catagen), and relative quiescence (telogen)35. 
With this “hair cycle,” the follicle demonstrates the unique ability to cyclically re-
generate itself during our lifetime, based on epithelial–mesenchymal interactions 
that drive waves of daughter cell populations, derived from resident epithelial, neu-
ral, and mesenchymal stem cells, into defined strata of differentiation88,146,195. The 
human scalp, eyebrows, and lashes consist of long, thick, medullated and pig-
mented terminal hair shafts, whereas the body is covered with short, thin and often 
unpigmented vellus hairs. Each of us displays an estimated total number of 5 mil-
lion hair follicles, of which 80,000 to 150,000 are located on the scalp. The hair 
length is defined by the duration of anagen, which lasts for 2 to 6 years. Approxi-
mately 85% to 90% of all scalp hairs are within anagen follicles. Catagen lasts only 
for a few weeks, followed by the telogen phase, which lasts 2 to 4 months. The 
usual growth of scalp hair follicles (i.e. the rate of hair shaft elongation) lies be-
tween 0.3 and 0.5 mm per day and is dependent on proliferation and subsequent 
follicular-type differentiation of the matrix keratinocytes in the hair bulb. The thick-
ness of the hair shaft is related to the size of the hair bulb33, which in turn is dic-
tated by the volume of the hair follicle’s mesenchymal component199. 
4.2 Hair Follicle Anatomy 
The mature anagen hair follicle is composed of a multicylindric stem that 
contains the hair shaft in its center and originates as an oval hair bulb proximally     
(Fig 1)207. Embraced by the hair bulb lies an onion-like structure, called the dermal 
papilla (DP) (sometimes referred to as the “follicular papilla” to avoid confusion 
with the most superficial region of the dermis). The DP functions as the “command 
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center” of the hair follicle and determines thickness, length, and likely the hair 
cycle itself146. 
Each hair follicle consists of epithelial and mesenchymal parts. The epithe-
lium is divided into an upper permanent region, distal to the arrector pili muscle 
(APM) and an inferior region (including the hair bulb), which dramatically reforms 
itself over the cycle (Fig.1,2). Apart from serving as the hair shaft factory, the    
anagen hair bulb also provides the hair shaft’s trichocytes with melanin granules. 
Within the hair bulb is a population of cells with the highest proliferation rate in the 
human body: the keratinocytes of the hair matrix. These can differentiate into 
trichocytes, or cells of the inner root sheath (IRS). The outer root sheath (ORS), 
hair matrix, and hair shaft derive from the epithelial stem cells in the bulge area, 
functioning as a pluripotent epithelial stem cell population for the skin                
(Fig. 2) 9,28,130. 
The size of the anagen hair bulb, the duration of anagen, and the hair shaft 
diameter are determined by the volume, the number of cells, and the secretory ac-
tivity of the DP82,148. Stringent coordination between epithelial and mesenchymal 
portions is needed to maintain the cyclic hair follicle growth195. Mesenchymal stem 
cells within the tissue sheath serve as a recruitment pool for new DP cells. Apart 
from mesenchymal stem cells, the hair follicle also contains mast cell precur-
sors81,90,134 and neuronal stem cells, the latter of which can develop into neurons 
and blood vessels1. The large numbers of stem cells make the hair follicle a fasci-
nating organ in the field of stem cell biology. 
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Figure 1. Hair follicle anatomy 
A) Anagen VI hair follicle ( IV is morphologic phase of anagen cycle). Histologic longitudinal section on the left 
hand side. Schematic drawing of an anagen VI follicle with anatomical details on the right hand side. B) Ana-
gen VI hair bulb in detail (enlargement of schematic drawing in A). APM, arrector pili muscle; CTS, connective 
tissue sheath; DP, dermal papilla; IRS, inner root sheath; ORS, outer root sheath; SG, sebaceous gland88 . 
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Figure 2. Structure of hair follicles during anagen, catagen and telogen stages of cycling ( Hematoxy-
lin and Eosin).  
A) a high magnification of hair bulb during the anagen (growth) stage (x100). B) a scalp-hair follicle during an-
agen stage (x25). C) a scalp-hair follicle during catagen (involutional) stage (x40). D) a scalp-hair follicle dur-
ing telogen (resting) stage (x25). In these panels, apm denotes arrector pili muscle, bg bulge, cl club hair, Cr 
cortex, Cu cuticle, cts connective-tissue sheath, dp dermal papilla, drm dermis, epi epidermis, hs hair shaft, 
iec involuting epithelial column, irs inner-rooth sheat, m matrix cells, ors outer root sheath, sc subcutaneous 
fat and sg sebaceous gland145  
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4.3 The Hair Cycle 
Hair cycling is the rhythmic change of the hair follicle through phases of 
growth (anagen), regression (catagen), and rest (telogen). Synchronized hair fol-
licle cycling (in mammals) prepares the hair coat for seasonal changes in habitat 
conditions as well as procreational activities195. The purpose of hair cycling in 
mammals with individual (asynchronous) follicle waves (e.g. humans) is not as ob-
vious, but may include cleaning the skin surface of debris and parasites, and ex-
cretion of deleterious chemicals by encapsulation within trichocytes195. In addition, 
follicle cycling might serve as a regulator of paracrine or even endocrine secretion 
of hormones and growth modulators produced within the follicle and secreted into 
the skin or circulation146. Finally, hair follicle cycling may act as a safe-guard 
against malignant degeneration by protecting rapidly dividing keratinocytes from 
oxidative damage by deletion during catagen88,144,146.   
4.3.1 Anagen 
Anagen (the growth phase of the hair cycle) is divided into 6 different 
stages defined by specific morphologic criteria148 (Fig. 3). During anagen, epithe-
lial stem cells differentiate into at least 8 different cell lines, forming the ORS, 
companion layer, Henle’s layer, Huxley’s layer, cuticle of the IRS, cuticle of the 
hair shaft, shaft cortex, and shaft medulla. The ORS probably is established by the 
downward migration of the regenerating epithelium174. IRS and hair shaft are tied 
together by their interlocked cuticle structures. The IRS-packaged shaft uses the 
innermost layer of the ORS (companion layer) as a slippage plane for orientation 
to move straight toward the skin surface76,136. 
Epithelial stem cells are located in the bulge area of the follicle. From   
there, in anagen stem cells ascend into the interfollicular epidermis and descend 
to differentiate into ORS cells. One hypothesis suggests that derivatives of stem 
cells from the bulge area reach the hair germ, transform into matrix keratinocytes, 
and rebuild the hair shaft139. During catagen, this stem cell population is situated 
lateral to the DP, protected from apoptosis and able to proliferate again in early 
anagen to produce a new hair shaft. 
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Hair shaft pigmentation only takes place in anagen. The cyclic reconstruc-
tion of an intact hair follicle pigmentary unit works optimally in scalp follicles during 
the first 10 hair cycles, meaning until approximately 40 years of age. Afterward 
there appears to be a genetically regulated exhaustion of the pigmentary potential 
of each individual follicle leading to “hair greying”201. 
4.3.2 Catagen 
The anagen period ends with a highly controlled involution of the hair follicle 
resulting in apoptosis and terminal differentiation. This process, called catagen, 
consists of 8 different stages. The hair follicle epithelium, neuroectodermal cell 
populations (melanocytes and Merkel cells), the mesenchyme, the perifollicular 
vascular system, and the follicular innervation all show cyclic changes in prolifera-
tion, differentiation, and apoptosis107,119,151. During catagen, the DP condenses, 
moves upward, and comes to rest beneath the bulge. The hairless gene (Hr) is re-
sponsible for the strong connection between the condensing DP and the diminish-
ing hair follicle epithelium in catagen and telogen follicles. In its function as a safe-
guard of apoptosis control during catagen140, Hr operates as a negative transcrip-
tion repressor and insures that apoptosis only takes place in certain tissues in the 
correct order.  
4.3.3 Telogen 
 
After regression, the hair follicle enters telogen, a phase of relative quies-
cence regarding proliferation and biochemical activity. The follicle remains in this 
stage until it is reactivated by intrafollicular and extrafollicular signals. The unpig-
mented club hair often remains stuck in the hair canal and is shed from the follicle 
during combing or washing. Most people lose 50 to 150 scalp hairs per day. The 
telogen stage typically lasts for two to three months before the scalp follicles re-
enter the anagen stage and the cycle is repeated.  
The percentage of follicles in the telogen stage varies substantially accord-
ing to the region of the body (e.g. 5 to 15 percent of scalp follicles are in the te-
logen stage at any one time, as compared with 40 to 50 percent of follicles on the 
trunk)145. 
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The chronology of hair follicle cycling is: 
catagen→telogen→anagen→catagen.  
Contrary to common misconception, morphologically, hair follicle cycling 
does not begin with anagen, but with catagen (Fig. 3) i.e., shortly after hair follicle 
morphogenesis has been completed. The initiation of hair follicle cycling via 
catagen induction is followed by a first, short phase of telogen, after which the first 
anagen development is seen195.  
The hair follicle has only one irreversible physiologic mechanism to break 
out of the hair cycle: programmed cell death, e.g. perifollicular inflammation that 
destroys the bulge region and therefore the follicle’s capacity to cycle40. This tar-
geted destruction probably serves to remove degenerated and nonfunctioning hair 
follicles. 
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Figure 3. Development and cycling of hair follicles.  
Selected stages of morphogenensis of hair follicles and three stages of follicular cycling (anagen, catagen and 
telogen) are shown. The roman numerals indicate morphologic sub-stages of anagen and catagen. The pie 
chart shows the proportion of time the hair follicle spends in each stage145. 
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4.4 Locally Produced Growth Factors, Hormones, and Proteins 
 
The hair follicle is not only a very productive source of pigmented hair 
shafts (keratins and melanin) but also of many growth-, pigment-, and immuno-
modulators. It can synthesize or metabolize an enormous number of hormones, 
neurotransmitters, neuropeptides and growth factors. For example, growth factors 
like TGF-β1/2, IGF1, HGF 48,75,108 and hormones like CRH, prolactin, cortisol, and 
melatonin47,77,87 are all synthesized in the hair follicle. Androgens are metabolized 
to dihydrotestosterone or 17β-estradiol, and proopiomelanocortin to ACTH, alpha-
MSH, or β-endorphin within the hair follicle195. The exact biological functions of the 
locally generated factors are not well understood. The hair cycle depends on this 
complex activity and on the expression of the specific matching receptors, sug-
gesting that these actions function as autocrine and paracrine mechanisms. 
As the hair follicle is regulated by diverse systemic extrafollicularly gener-
ated hormones and growth factors and by a variety of self-generated substances, 
it is no surprise that even small changes in this sensitive milieu can lead to a 
shortening of anagen, an induction of catagen, and to an increased number of te-
logen follicles, resulting in telogen effluvium. 
4.5 Key Factors in Hair Follicle Cycling 
 
It is now widely accepted that hair follicle transformation during cycling is 
caused by alterations in the local signaling milieu. There are key regulators that 
build up local gradients with competing stimulating and inhibitory signals (Fig. 4). 
Rhythmic changes of signal transducers in the key compartments of the follicle 
(bulge, secondary hair germ, dermal papilla) are thought to drive cyclic hair follicle 
transformation. 
Key factors known to induce anagen include soluble proteins of the WNT 
family, activation of the corresponding β-Catenin pathway, noggin, and the tran-
scription factor STAT314,128. Sonic hedgehog, HGF, and FGF7 (KGF) support this 
process and stimulate the subsequent steps of anagen development32,108,182.    
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DP-induced keratinocyte differentiation occurs via β-catenin/lef1 signaling178. Hair 
shaft differentiation seems to be mediated, at least in part, by desmoglein124. WNT 
signals (WNT3a and WNT7a) are capable of keeping the dermal papilla in anagen. 
IGF1, HGF, glial cell-derived neurotrophic factor, and vascular endothelial growth 
factor can prolong anagen (Fig. 4)42,69,108,111,119,128,135,149,161. During the anagen–
catagen transformation of the hair follicle, the transcription factor Hr is a central, 
indispensable element of navigation and coordination of signal transduction. Loss 
of Hr function leads to rapid degeneration of the hair follicle138. Certain members of 
the homeobox gene family also seem to control some of the named factors. TGF-
β1, TGF-β2, FGF-5, the neurotrophins NT3, NT4, BDNF, p75, also retinoids, 
prolactin, and several other candidates like thrombospondin 1 and vanilloid recep-
tor 1 induce catagen10,13,47,48,50,79,192,196,210. An essential inhibition/disinhibition sys-
tem in anagen development is the neutralization of BMP4 by noggin15. Anagen is 
terminated by the upregulation of hair growth inhibitors (TGF-β1, TGF-β2, FGF-5) 
and downregulated by anagen preserving factors (IGF-1, HGF, FGF-5S) at the 
same time.  
It seems confusing that some hair growth modulators have growth-
stimulating effects during morphogenesis but inhibitory effects in the hair cycle. 
TGF-β2, follistatin, and NT3, for example, accelerate hair follicle morphogenesis, 
but are catagen-inducing in mature anagen follicles14,49,131,146. Some of the very 
potent signal transducers of anagen induction or termination could lead to the de-
velopment of specific pharmacologic agents that could manipulate the human hair 
cycle and treat hair growth disturbances more efficiently. However, none of these 
factors seems to be a key element of the hair cycle clock itself, which directs the 
factors to execute the cyclic hair follicle transformations. 
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Figure 4. Molecular players in hair cycle control.  
The figure shows key factors of hair follicle cycling being employed by the hair cycle control to drive the hair 
follicle from one stage to the next one or to keep it in a given stage. However, none of the named mediators 
are known to be key elements of the central pacemaker. (For references, see text). APM, arrector pili muscle; 
CTS, connective tissue sheath; DP, dermal papilla; IRS, inner root sheath, ORS, outer root sheath; SG, seba-
ceous gland; BMP, bone morphogenic protein; WNT, wingless; STAT3, signal transducer and activator of 
transcription 3; FGF7, fibroblast growth factor 7; HGF, hepatocyte growth factor; Shh, sonic hedgehog; IGF1, 
insulin like growth factor; CTSL, cathepsin L; cutl, transcriptional repressor; GDNF, glial cell line-derived neu-
rotrophic factor; BDNF, brain-derived nerve growth factor; VEGF, vascular endothelial growth factor; ATRA, 
all-trans retinoid acid; RXR, retinoid x receptor; RAR, retinoid acid receptor; NGF, nerve growth factor; Lef1, 
lymphoid enhancer-binding protein; TGFβ, transforming growth factor β; p75NTR, low affinity neurotrophin re-
ceptor; PRL, prolactin; PRLR, prolactin receptor; IFNγ, interferon γ; ER, estrogen receptor; IL1, interleukin 1; 
VR1, vanilloid receptor 1; TNFα, tumor necrosis factor α; TSP1, thrombospondin 1; (modified after Paus and 
Peker149). 
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4.6 Sex Hormones as Potent Hair Growth Modulators 
Androgens are very potent, yet non-essential, hair growth modulators. In 
hair growth regulation, different types of hair follicles in diverse body areas have 
different underlying cycle control mechanisms. A common example is the para-
doxical effect of androgens on terminal follicles of the scalp compared with vellus 
follicles on other parts of the body. Androgens stimulate hair growth in non-scalp 
areas like the beard, breast or abdomen (at least in part by upregulation of gene 
expression and secretion of IGF1)75. In contrast, androgen sensitive hair follicles of 
the scalp become smaller under the influence of androgens (miniaturization) lead-
ing to the typical changes of androgenetic alopecia33,70. Inhibition of hair growth in 
the fronto-temporal region can be demonstrated by TGF-β stimulation74. Current 
theories suggest that scalp and body hair follicles react to androgen stimulation 
differently by triggering programmed gene regulation of defined hormones. These 
gene programs lead to potent hair growth stimulation in one follicle population and 
growth inhibition in others117.  
Localization and gender-specific regulation of hair follicle gene expression 
has also been demonstrated for estrogens. In vitro experiments show an inhibition 
of hair shaft elongation and anagen prolongation in human female occipital hair 
follicles, whereas in male frontotemporal scalp follicles, 17β-estradiol (E2) stimu-
lates hair shaft elongation25. In vivo E2 also leads to anagen prolongation in hu-
man hair follicles186. 
4.7 Management of Hair Growth Disorders 
 
Hair loss, as well as unwanted hair growth (hirsutism, hypertrichosis), is a 
widespread problem. According to one calculation, androgenetic alopecia on its 
own eventually affects approximately 50% of the world’s adult population145,206. 
The hair shaft, the main product of the hair follicle, serves as an instrument of so-
cial communication, a protective device, and as a container for sequestering and 
excreting unwanted compounds145,195.  
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Given the role of hair in psychosocial communication, (as a symbol of 
youth, health, fertility, and sexual potency) hair loss often has an underestimated 
psychosocial impact on an individual’s self-esteem, interpersonal relationships, 
and positioning within society57. Telogen effluvium, androgenetic alopecia, and 
alopecia areata, the 3 most frequent hair loss disorders encountered in clinical 
practice, exemplify how a range of negative psychological and social experiences 
translate into significant stressors that possibly conspire to further aggravate hair 
loss2-4,57. The majority of the known hair growth disorders are a consequence of 
changes in the hair cycle. The most frequent growth disorder in men and women is 
androgenetic alopecia (AGA). AGA is characterized by a shortening of the ana-
gen phase and a prolongation of telogen, combined with miniaturization of hair fol-
licles33. These changes are androgen dependent and genetically determined. The 
underlying molecular mechanism depends on the conversion of testosterone to di-
hydrotestosterone by 5α-reductase. Dihydrotestosterone binds to androgen recep-
tors of the hair follicle and leads to a shortening of anagen and a reduced cell hair 
matrix volume31,120. Men and women with AGA have a higher activity of 5α-
reductase type II and androgen receptors in the frontal scalp area compared with 
the occipital area170. However, simply removing androgens does not usually result 
in the conversion of miniaturized follicles to terminal ones; thus, current treatments 
for advanced androgenetic alopecia, including minoxidil and finasteride, are usu-
ally ineffective. 
The transient shedding of hair - telogen effluvium - that is associated with 
drugs, fever, endocrine abnormalities, parturition, anemia, and malnutrition occurs 
when an increased number of hair follicles prematurely enter the telogen stage 
and then shed their hair shafts. Transient shedding typically begins two to four 
months after the inciting event and lasts for several months145. Regrowth routinely 
follows, barring any metabolic or nutritional deficiency.  
In contrast to androgenetic alopecia, hirsutism and hypertrichosis result 
from an extended anagen stage with an abnormal enlargement of hair follicles. 
Small vellus hairs are transformed into large, terminal hairs. Depilatory creams 
and waxes, the usual treatments, alleviate the problem only temporarily, because 
irritation or plucking rapidly induces the anagen stage and hair-follicle growth145. 
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Electrolysis and selective photothermolysis with the use of lasers destroy the hair 
shaft, outer root sheath, bulge, and dermal papilla of the hair follicles145. The ex-
tent of the destruction determines whether the follicle regenerates.  
Some types of inflammatory alopecias (such as those caused by lichen 
planopilaris and discoid lupus erythematosus) are scarring and permanent, 
whereas others (such as alopecia areata) are nonscarring and reversible145. In 
scarring alopecias, the inflammation usually involves the superficial portion of the 
follicle, including the bulge area, suggesting that the stem cells necessary for the 
regeneration of the follicle are irreversibly damaged. In contrast, the acute follicular 
inflammation in alopecia areata attacks the hair bulb in the subcutaneous fat145. 
This inflammation terminates the anagen stage, forcing the follicles into the 
catagen stage. However, because the bulge area is spared, a new hair bulb and 
hair shaft grow at the start of the anagen stage, once the inflammation has sub-
sided or has been blunted with glucocorticoids.  
Antineoplastic drugs disrupt the rapidly proliferating bulb matrix cells. As 
a result, hair production ceases, and the hair shaft becomes narrower, with subse-
quent breakage and loss of the hair. Because the hairs that are lost are those in 
the anagen stage, this phenomenon is called anagen effluvium. The stem cells of 
the hair follicles are spared, presumably because of their slow cycling, and they 
subsequently generate a new hair bulb. Radiation therapy can also result in re-
versible anagen effluvium. However, high doses of radiation (50 to 60 Gy) typically 
cause permanent alopecia, probably because of the destruction of the epithelial 
stem cells or the dermal papilla145.  
Figure 5 illustrates how common hair growth disorders can be managed by 
manipulating the hair cycle at different time points. AGA and telogen effluvium 
could be treated by inhibiting premature catagen transition and/or stimulating the 
telogen/anagen transformation. Catagen induction and arrest of follicles in a pro-
longed telogen stage may be a therapy for hypertrichosis and hirsutism. 
A better understanding of the stem cell rich bulge region and the induction 
of secondary hair germ by DP signals could help narrow the search for tools that 
would limit the hair follicle miniaturization and loss seen in AGA. The discovery of 
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the enigmatic hair cycle clock is still the greatest challenge in hair research, and 
the one most likely to result in satisfactory treatment options in the field of hair 
growth disorders. 
 
 
Figure 5.  Management of hair growth disorders by hair cycle manipulation. 
Common hair growth disorders frequently arise from changes of the hair cycle. They can be managed by ma-
nipulating the length of the different hair cycle stages. Anagen: growth phase with active production of a pig-
mented hair shaft, maximal length and volume of the follicle; catagen: apoptosis-driven phase of hair cycle re-
gression with cessation of hair shaft production and pigmentation and club hair formation; telogen: phase of 
relative quiescence of hair follicle activity, exogen: active shedding of club hair;  +, stimulate;  −, inhibit (modi-
fied after Paus145). 
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5 Study Aims 
“The Development of an Organotypic Folliculoid Assay Systems 
for the Exploration of Epithelial-mesenchymal Interactions in the 
Human Hair Follicle" 
 
 
Worldwide annual investments made by consumers into manipulating their 
hair growth by pharmaceutical agents, cosmetics and/or nutraceuticals represent a 
major incentive for the pharmaceutical industry to develop new, and hopefully 
more effective hair growth-modulatory agents. 
The search for such agents is, however, severely handicapped by the lack 
of satisfactory three-dimensional (3D) in vitro screening systems that sufficiently 
mimic important epithelial-mesenchymal interactions as they occur in human hair 
follicles (HF). 
 
The main aim of this study was therefore to develop an organotypic folliculoid 
(hair follicle-like) assay system (equivalent) that provides well-defined basic pa-
rameters for detailed exploration of epithelial-mesenchymal interactions in the hu-
man hair follicle. Furthermore the assay system should also serve as a screening 
tool for potential hair drugs modulators. 
 
5.1 Criteria for the Development of Folliculoid Equivalent 
 
The complexity of epithelial-mesenchymal interactions that underlie HF 
growth and cycling makes it unlikely that these will ever be fully reproduced in vi-
tro. Therefore, when designing a human folliculoid in vitro system it is important to 
define the criteria that such an organotypic system should meet in order to mimic 
in vivo situation as closely as possible. Our 3D system should fulfill the following 
basic criteria:  
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1. Imitate at least some essential epithelial-mesenchymal interactions charac-
teristic for human HF biology; 
2. Show expected responses to recognized hair growth-modulatory agents; 
and  
3. Provide a reasonable predictive value on how human HF will respond to the 
same test agent in vivo.  
 
The work during this study was divided into 2 major parts including several 
objectives: 
 
Part I:   
To develop an organotypic system, which meets given criteria and provide well-
defined basic parameters for quantitatively assessing the modulatory effects of a 
given test agent. 
 
Part II: 
To optimize existing system into high-throughput screening assay to allow to test 
standard hair growth- modulatory agents and to study in more detail the basic mo-
lecular processes involved in HF growth and development. 
 
 
Objectives: 
• To establish hair follicle cell cultures 
• To design a structure of the folliculoid equivalents 
• To produce well-reproducable hair equivalents with a large number 
of test units 
• To optimize the culture condition of the equivalents 
• To prove the suitability of the systems for investigation of the effects 
of  hair growth-modulatory drugs 
• To prove the suitability of the systems as a discovery tool for the 
identification of the target genes and the global gene expression pro-
file 
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6 Materials and Methods 
 
6.1 Cell isolation and cell culture 
 
ORS keratinocytes were isolated from plucked anagen HF by trypsiniza-
tion106. Primary cultures of ORSK were then cultured on feeder layer of X-ray irra-
diated human dermal fibroblasts (HDF), obtained from human skin from de-
epidermized dermis using enzymatic digestion 102, in defined keratinocyte medium 
(SFM, Invitrogen, Paisley, UK) supplemented with 0.1 nmol L-1 cholera toxin, 5 μg 
mL-1 insulin, 0.4 μg mL-1 hydrocortisone, 2.43 μg mL-1 adenine, 2 nmol L-1 triiod-
thyronine, 10 ng mL-1 epidermal growth factor, 1 mmol L-1 ascorbyl-2-phosphate, 
and antibiotics penicillin G, gentamicin (all reagents purchased from Sigma-
Aldrich, Taufkirchen, Germany). Cells at early passage (2-4) were used. 
 
After microdissection of anagen VI HF from scalp-skin biopsies using a 
method modified according to Philpott 159, isolation of DPC from HF were estab-
lished according to Magerl115 and cultured in Chang medium (Trinova, Santa Ana, 
CA, USA) with 10% fetal bovine serum (FBS, Biochrom KG, Berlin, Germany) 
123,204. The cell passages of 1-2 were used. 
 
6.2 Preparation of human organotypic folliculoid “sandwich” systems  
 
Two different organotypic co-cultures were prepared based on previously 
described 3D systems by Limat104 and Stark193, with the basic modifications indi-
cated in Fig. 6B and C.  
 
In the first system (“layered sandwich”, Fig. 6B), dermal equivalents were 
prepared from collagen type I extracted from rat tail tendons (BD Biosciences, 
Bedford, MA, USA) at a final concentration of 4 mg mL-1. Eight volumes of ice-cold 
collagen solution were mixed with 1 volume of 10x Hank´s buffered saline (Invitro-
gen) followed by neutralization with 1 M NaOH. One volume of FBS was added 
with suspended HDF (passages 2-8) and mixed thoroughly resulting in final con-
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centration of 3.2 mg mL-1 collagen and 2.5 x 105 cells mL-1. Of this mixture, 1.5 mL 
each were poured into a 24-multiwell dish (Corning Costar, Corning, NY, USA) 
and allowed to gel at 37°C. After polymerization, Dulbecco’s modified Eagle’s me-
dium (DMEM, Invitrogen) with 10% FBS was added up to the upper edge of the 
well 52,188. The gels were cultivated under submerged conditions for 5 days, with 
changes of medium every other day. After this period the gels were maximally 
contracted and were used as pseudodermis. The pseudodermis was transferred 
by forceps into tissue culture transwells (pore size 0.4 μm, polycarbonate, Corning 
Costar) and overlaid with 0.1 mL of suspension of DPC in Matrigel™ Basement 
Membrane Matrix (BD Biosciences) at a concentration of 1x106 DPC mL-1. The 
suspension geled within a few minutes at 37 °C, and then Chang medium204 was 
added into the wells and cultured for 24 hours submerged. After this, the medium 
was removed and 1x105 ORSK (passage 2-4) in 0.1 mL of different media (see be-
low) were seeded on top of the gels, 5 samples per each medium were prepared. 
Another 24 hours later, when the ORSK already had formed a sheet and had at-
tached to the top of the pseudodermis with MatrigelTM + DPC layer, more medium 
was added until the entire sandwich system was submerged. Culture was per-
formed for 14 days with medium changes every other day (note that previously 
published systems were cultured at the air-liquid interface101,193  [see Fig. 6A], as 
opposed to the submerged conditions described herein). 
 
The second, newly developed “folliculoid” 3D system (“mixed sandwich”) 
(Fig. 6C) was prepared in an identical manner to the one described above, until 
the contracted pseudodermis had been transferred into tissue culture transwells. 
Then, a mixture of ORSK (1x106 cells  mL-1, passage 2-4), DPC (1x106 cells mL-1, 
passage 1-2) in 1 volume of fetal clone II (FC, Perbio Science, Erembodegem-
Aalst, Belgium), and the Matrigel™ matrix (9 volumes) was prepared and 0.1 mL of 
this suspension was poured on the top of the pseudodermis. The suspension 
geled within a few minutes at 37 °C and the different culture media were added 
into the wells (5 samples per each group) and the culture was submerged as de-
scribed above. The experiments were repeated 3 times. 
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Throughout the experiments, three different culture media were used: 
Culture medium 1. Composed of 3 parts of DMEM, mixed with 1 part of Ham´s 
F12 (Sigma-Aldrich) supplemented with 10% fetal clone (FC), 0.1 nmol L-1 cholera 
toxin, 5μg mL-1 insulin, 0.4 μg mL-1 hydrocortisone, 2.43 μg mL-1 adenine, 2 nmol 
L-1 triiodthyronine, 10 ng mL-1 human recombinant epidermal growth factor, 1 
mmol L-1 ascorbyl-2-phosphate and antibiotics penicillin G, gentamicin. (modified 
from Smola21) The calcium concentration of this medium was 1.9 mmol L-1.  
Culture medium 2. Similar component found in medium 1 but without FC. The 
calcium concentration of this medium was 1.8 mmol L-1. 
Culture medium 3. Defined keratinocyte medium SFM (Invitrogen) supplemented 
with 0.1 nmol L-1 cholera toxin, 5 μg mL-1 insulin, 0.4 μg mL-1 hydrocortisone, 2.43 
μg mL-1 adenine, 2 nmol L-1 triiodthyronine, 10 ng mL-1 epidermal growth factor, 1 
mmol L-1 ascorbyl-2-phosphate, and antibiotics (penicillin G, gentamicin). The me-
dium did not contain FC and the calcium concentration45 was 0.15 mmol L-1. 
 
6.3 Preparation of Human Folliculoid Microspheres (HFM) 
 
The following described method of HFM preparation has been patented un-
der patent EP1231949. A beaker containing two phases of immiscible autoclaved 
liquids [lower phase: 250 ml of perfluorether (Fluorinert™ FC-40, 3M, Germany); 
upper phase: 500 ml of defined triglyceride mixture (Miglyol, Hüls, Germany)] was 
prepared and warmed up to 37 °C with continuous magnetic stirring to prevent 
sedimentation and attachment of prepared HFM (see below). 
 
Then a cell-matrix mixture of HFM was prepared, following the optimized 
protocol for the previously described64 preparation of the “mixed sandwich” 3D 
system. Mixture of collagen I and Matrigel™ Basement Membrane Matrix (ratio 
4:1) was used as a matrix for cells. Ice-cold collagen type I extracted from rat tail 
tendons (BD Biosciences, Bedford, MA, USA) at a final concentration of 4 mg/ml 
was mixed with 10x Hank´s buffered saline (Invitrogen) followed by neutralization 
with 1 M NaOH (Invitrogen), then an appropriate volume of Matrigel™ (BD Biosci-
ences) was added and mixed. One volume of FBS with resuspended cells (ORSK 
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and DPC in the ratio 1:2) was then added to the matrix and mixed thoroughly (the 
cell density of ORSK was 1 x 106 cells mL-1 and of DPC was 2 x 106 cells mL-1). A 
1 ml syringe was filled with the above cell-matrix suspension and, by gently press-
ing the syringe, small droplets were placed into the Miglyol-FC-40 mixture and 
formed HFM by way of a gelling process at 37 °C 8. The HFM were left in this liq-
uid for 5 min (with continuous stirring), then removed with a net, washed immedi-
ately in the culture medium and then placed in culture Petri dishes. The HFM were 
cultivated submerged in the aforementioned (see cell isolation and cell culture) 
supplemented low-calcium (0.15 mM) SFM for 10 days (Fig. 13A). Under these 
conditions, the average size of the HFM was 1.73 ± 0.33 mm on day 0 and 1.03 ± 
0.20 on day 7. In order to determine the effects of high calcium content in growth 
media, a medium with a calcium concentration of 1.8 mM was used in some ex-
periments. This (also serum-free) solution was composed of three parts of Dul-
becco’s Modified Eagle’s Medium (DMEM), one part of Ham´s F 12 (both from 
Sigma), and the above additives. 
 
The agents investigated were resuspended in the appropriate vehicle and 
were added to the medium on day 0. The medium was changed on days 3 and 7, 
and collected for LDH analysis (see cytotoxicity assay). HFM (20-30 per group) 
were cultured submerged in culture medium, and one third of the samples were 
collected on days 3, 7 and 10. 
 
6.4 Histology and quantitative histomorphometry 
 
For morphological analysis of folliculoid “sandwich” systems, the specimens 
were fixed in 4% formaldehyde (in phosphate-buffered saline, PBS, pH 7.4) for 24 
hours. After dehydration, samples were embedded in paraffin and 5 µm sections 
were stained with hematoxylin-eosin (HE). On these sections, the quantitative 
evaluation of the spheroid diameter was also performed. Using a calibrated ocular 
eye-piece of a light-microscope (Olympus Optical Co., Japan), the largest diame-
ter of the spheroids was measured in 3-5 samples per group (at least 75 spheroids 
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from 3-5 different folliculoid systems were measured per group). The statistical 
analysis was performed as described in section 6.9. 
For morphological analysis of the HFM, samples were embedded into 
Thermo Shandon Cryochrome solution (Thermo Shandon Inc., Pittsburgh, PA, 
USA) and frozen in liquid nitrogen vapor. 8 μm thick sections were then cut, and, 
after fixation in ice-cold acetone, the samples were stained with hematoxylin-eosin 
(Sigma). 
 
6.5 Immunofluorescence 
 
Samples were embedded in Thermo Shandon Cryochrome solution 
(Thermo Shandon Inc., Pittsburgh, PA, USA) and frozen in liquid nitrogen vapor. 
Cryosections, made at 8µm settings, were mounted on silane coated slides, and 
air dried. Sections were then fixed for 10 minutes in acetone at –20 °C, rehydrated 
in phosphate-buffered saline (PBS), and then were pre-incubated with 10% serum 
species of the secondary antibody for 20 minutes. For immunofluorescence label-
ing, the following primary antibodies were used: mouse anti-cytokeratin 6 (CK6, 
clone KA12, 1:10, Progen, Heidelberg, Germany) to identify ORSK; mouse anti-
large proteoglycan versican (Versican, 1:500, Seikagaku Corporation, Tokyo, Ja-
pan) to identify DPC; mouse anti-fibronectin (1:10, Acris, Hiddenhausen, Ger-
many); mouse anti-c-kit/scattered factor (SCF, 1:100, Santa Cruz Biotech, Santa 
Cruz, CA, USA); rabbit anti-transformig growth factor-β2 (TGFβ2, 1:50, Santa Cruz 
Biotech). Sections were then labeled with appropriate fluorescein isothiocyanate- 
(FITC) or rhodamine-conjugated goat anti-mouse or anti-rabbit secondary antibod-
ies (Jackson ImmunoResearch, West Grove, PA, USA). For positive controls for 
both CK6 and versican, cryosections of human HF11,92,93 were used and stained 
similarly as described above. 
 
To assess proliferation of different cell types in organotypic co-cultures, double 
immunolabeling was performed. For detection of proliferation in the ORSK and 
DPC, sections were incubated overnight with the first primary antibody against the 
recognized proliferation marker Ki67 (1:10 of rabbit anti-human Ki67, Zymed, San 
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Francisco, CA, USA) at 4 °C, then with the first secondary antibody (goat anti-
rabbit, FITC-conjugated) for 45 minutes at room temperature. The samples were 
then incubated with either an antibody against CK6, which is not expressed by 
normal epidermal keratinocytes, yet characteristic for normal ORSK (1:10 of 
mouse anti-human CK6, Progen) 93,94 or with an antibody against the DPC-specific 
extracellular matrix antigen, Large proteoglycan Versican (Seikagaku Corporation, 
Tokyo, Japan) 84,85,191 for 1 h at 37 °C. Finally, the second secondary antibody 
(goat anti-mouse, rhodamine-conjugated) was applied for 45 minutes at room 
temperature. Sections were then washed in PBS, counterstained with DAPI (4′,6-
Diamidin-2-phenylindol fluorescent stain) (Sigma) and mounted with Fluoromount 
G (Southern Biotechnology Associates, Birmingham, AL, USA). 
 
For measurement of apoptosis in the ORSK and DPC, a similar double 
staining protocol was used. In this case, however, instead of Ki67 labeling, com-
ponents of an ApopTag TUNEL (terminal dUTP nick-end labeling) Apoptosis As-
say Kit (Intergen, Purchase, NY, USA) were used following the instructions sug-
gested by the manufacturer. 
 
6.6 Cytotoxicity assay 
 
To assess the presence of necrotic cells within the HFM, a Lactate-
Dehydrogenase (LDH)-based Cytotoxicity Assay was applied (Bio Vision, Moun-
tain View, California,USA). Briefly, the culture media of the HFM of all treated 
groups were collected on days 3, 7 and 10 and the amount of LDH, as a marker of 
necrotic cell death, was colorimetrically determined according to the protocol sug-
gested by the manufacturer. 
 
 
 
6.7 Semi-quantitative RT-PCR technique 
 
The expression of mRNA for TGFβ2 and SCF in HFM (and in microdis-
sected human scalp hair follicles, used as positive controls) was determined by 
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semi-quantitive RT-PCR. The total RNA was extracted using the RNA easy kit 
(Qiagen, Hilden, Germany) and then was reverse transcribed with random primers 
and reverse transcriptase provided in 1st Strand cDNA Synthesis Kit for RT-PCR 
(Boehringer Mannheim, Mannheim, Germany). Subsequent PCR amplification (94 
°C for 5 min; 30 cycles of 94 °C for 30s, 57 °C for 60s, 72 °C for 60s; 72 °C for 10 
min) was performed on the UNO-Thermoblock (Biometra, Göttingen, Germany) 
with the following primers (all from Sigma): TGFβ2, 5'-ATC CCG CCC ACT TTC 
TAC AGA C-3' and 5'-CAT CCA AAG CAC GCT TCT TCC-3' (GenBank accession 
number: Y00083); SCF, 5’-ATT CAA GAG CCC AGA ACC CA and CTG TTA ACC 
AGC CAA TGT ACG (GenBank accession number: M59964); β-actin, 5'-CGA CAA 
CGG CTC CGG CAT GTG C-3' and 5'-CGT CAC CGG AGT CCA TCA CGA TGC-
3' (GenBank accession number: NM001101). The PCR products were visualized 
on a 2 % agarose gel with ethidium bromide, and the photographed bands were 
quantified by Image Pro Plus 4.5.0 software (Media Cybernetics, Silver Springs, 
MD, USA). 
 
6.8 Microarray gene expression analysis 
 
The microarray experiment was based on two-color ratio hybridization and 
a Low RNA Input Fluorescent Linear Amplification kit (Agilent Technologies, 
Böblingen, Germany) for RNA labeling. In short, 500 ng of total RNA (isolated from 
control and treated HFM as described above) was reverse transcribed with an 
oligo(dT)-T7 promoter primer and Moloney murine leukemia virus-reverse tran-
scriptase (MMLVRT, Applera, Darmstadt, Germany) in order to synthesize first 
and second-strand of cDNA. Fluorescent antisense cRNA was synthesized with 
T7 RNA polymerase, which simultaneously incorporated either cyanine 3-cytidine 
5'-triphosphate (3-CTP) or cyanine 5-CTP (both from Cy Scribe, Amersham, 
Freiburg, Germany). The purified products were quantified by absorbance at A552 
nm for cyanine 3-CTP and A650 nm for cyanine 5-CTP, and labeling efficiency 
was verified with a Nanodrop photometer (Kisker, Steinfurt, Germany). Before hy-
bridization, 2 μg of each labeled cRNA product was fragmented and mixed with 
control targets and hybridization buffer according to the supplier’s protocol (Agilent 
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Technologies). Hybridization was done overnight for 19 hours at 60°C. The slides 
were then washed according to the manufacturer’s manual, and the scanning of 
microarrays was performed with 5-μm resolution using a DNA microarray laser 
scanner (Agilent Technologies). Features were extracted with an image analysis 
tool version A 6.1.1 (Agilent Technologies) using default settings. Data analysis 
was conducted on the Rosetta Inpharmatics Platform Resolver Built 4.0. Expres-
sion patterns were identified by stringent data analysis using a 2-fold expression 
cut-off and exclusion of data points with a low p value (p < 0.01). By using this 
strategy, data selection was independent of error models implemented in the 
Rosetta Resolver system. 
 
6.9 Statistical analysis 
 
In order to compare the proliferation and apoptosis of cells in the organo-
typic co-cultures, the percentage of Ki67-positive (proliferating) or TUNEL-positive 
(apoptotic) cells was determined (both in ORSK and in DPC) in at least 5 samples 
per group for each experiment. From TUNEL staining the apoptotic cells were dis-
tinguished from necrotic cells according to the morphological criteria and only 
apoptotic cells were assessed. The values were then averaged and were ex-
pressed as mean ± SD. Statistical analysis was performed using Mann-Whitney 
nonparametric test. Two types of statistical comparison were carried out for sand-
wich system. First, to reveal the differences between the different media within the 
given co-culture, the values obtained in the 3 different media were compared to 
one another either in the “layered” or in the “mixed” cultures. Then, to assess dif-
ferences between the two co-cultures, values obtained in the given culturing me-
dium in the “layered” sandwich were compared to those of the “mixed” one cul-
tured in the same medium. P values < 0.05 were regarded as significant. A similar 
comparison was performed during the determination of the averaged cluster size 
and the average number of CK6+ ORSK and Versican+ DPC. 
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7 Experimental work 
7.1  Experimental Part I - “Sandwich” system 
 
Development of a Basic Organotypic Assay System that Imitates Human Hair 
Follicle-like Epithellial-Mesenchymal Interactions. 
 
7.1.1 Introduction 
 
The cyclic growth and regression activity of the HF is the result of bi-
directional epithelial-mesenchymal interactions27,82,120,122,139,145,176,195. Even though 
the complexity of these interactions makes it unlikely that they can be fully repro-
duced in vitro, simplified in vitro-assay systems are required that attempt to imitate 
at least some key aspects of these interactions in a three-dimensional (3D) or-
ganotypic context52,101,102. Such assay systems hopefully will not only offer (ur-
gently needed) hair research alternatives to the use of intact, organ-cultured hu-
man scalp HF 159, whose supply is very limited, but should also facilitate dissection 
of the as yet obscure molecular signaling principles that govern epithelial-
mesenchymal interaction in the human HF (as opposed to the murine system, 
where due to the availability of numerous instructive mouse mutants with defined 
hair growth abnormalities27,131 the molecular basis of epithelial-mesenchymal in-
teractions in the HF during morphogenesis and cycling is already much better un-
derstood 27,145,195).  
 
Many different 3D organotypic assay systems on the basis of human skin 
cell populations have been developed for investigative dermatol-
ogy5,101,104,116,193,211. These allow to study, for example, the role of diffusible factors 
affecting epithelial-mesenchymal interactions, the dynamics of basement mem-
brane formation and to test the effects of various modulators, growth hormones, 
nutrients, etc.19,112,113,188-190. These human skin equivalents have become an indis-
pensable alternative to animal models in pharmacological and toxicological in vitro 
testing53,167. As long as human HF epithelial stem cells and human hair matrix 
keratinocytes cannot be easily dissected, cultured and propagated in vitro without 
 
 
   Hair Equivalents
 
 Page 44 of 107 
 
loosing their in vivo-characteristics95, it would be naive to expect that human HF-
like structure can be reconstructed in vitro with such relative ease as is now the 
case for human epidermis and dermis. However, the characteristic mesenchymal 
component of the human HF, the highly specialized, inductive dermal papilla fibro-
blasts (DPC), can readily be dissected, cultured and propagated115,123 as is the 
case for human outer root sheath keratinocytes (ORSK) 101,102,104,106. Therefore, 
these cell populations offer themselves to be employed as the basis for any hu-
man folliculoid in vitro system. 
 
When designing a human folliculoid in vitro system it is important to define 
the criteria that such an organotypic assay should meet in order to support the 
claim that it imitates the in vivo situation as closely, yet also as pragmatically and 
economically, as possible. Based on our current limited knowledge of human HF 
biology 80,122,139,145, we propose that the following minimal criteria should be met: 
 
1. Given that direct interactions of the HF epithelium and the HF mes-
enchyme via native extracellular matrix are crucial for normal HF 
functions104,109 , ORSK and DPC should be physically interacting un-
der 3D conditions. 
2. The extracellular matrix through which these interactions are occur-
ring should also contain basement membrane components, since HF 
epithelium and mesenchyme are interacting via a basement mem-
brane-like extracellular matrix 29,30,121,205. 
3.  Morphologically, the 3D system should allow the epithelial HF cells 
to form - ideally concentric - cell aggregates in order to mimic com-
pact, functionally linked epithelial tissue compartments as they occur 
in the outer and inner root sheaths or the hair matrix of the HF in 
vivo. 
4. While the epithelial HF cells should show substantial proliferation, 
HF-type keratinization (e.g. cytokeratin-6 [CK6] expression92,93) and a 
low level of apoptosis, the HF mesenchymal cells used in such a 3D 
system should show minimal proliferation and minimal apoptosis (as 
 
 
   Hair Equivalents
 
 Page 45 of 107 
 
is characteristic for the follicular dermal papilla in vivo 27,107,199 and 
should display secretory activities that distinguish HF fibroblasts from 
interfollicular dermal fibroblasts such as strong expression of versi-
can. This proteoglycan, the expression of which correlates well with 
the hair inductive ability of DPC, was shown to act as a specific 
marker of matrix changes in the unique papilla extracellular matrix to 
promote HF development and cycling36,86.  
5. As in vivo, the interaction of HF epithelium and mesenchyme should 
be supported by a fibroblast-contracted collagen type I gel that re-
sembles the interfollicular dermis. 
6. Finally, in contrast to skin equivalents, “folliculoid” 3D systems should 
not be cultured at the air-liquid interface, but should be kept under 
continuously submerged culture conditions, since almost the entire 
HF epithelium lives under fully “submerged” conditions in vivo. 
 
Historically, normal human epidermal keratinocytes (NHEK) were first used 
in organotypic 3D systems112,189,190,193 and later ORSK were also em-
ployed101,102,104. In these systems were cells layered above collagen I  or collagen I 
mixed with human dermal fibroblasts (HDF) forming pseudodermis15,193. Later, 
these collagen I gels or a pseudodermis were covered with various cell and matrix 
mixtures, which contained basement membrane and extracellular matrix compo-
nents (Matrigel™), NHEK or ORSK, plus mesenchymal cells (HDF or DPC) in a 
number of different designs (see Fig. 6A) 101,193. Ultimately, all these previously 
reported 3D systems with HF cell populations were cultured at the air-liquid inter-
face. The comprehensive data on the ratio of proliferation/apoptosis of ORSK and 
DPC in these systems, and on HF-like differentiation markers (e.g. CK6 for ORSK, 
versican for DPC 36,86 ) were not assessed in the classical studies that have pio-
neered the field 101,104,113,189,190,193 . 
 
The aim of the present study, therefore, was to develop the first organotypic 
“folliculoid” 3D system that meets all of the above six criteria (as pragmatically and 
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economically as possible), and provides well-defined basic parameters for quanti-
tatively assessing the modulatory effects of a given test agent.  
 
In order to achieve this, we developed two continuously submerged 3D sys-
tems, whose basic design principle is outlined in Fig. 6B and C: In the “layered 
sandwich” (Fig.6B), the pseudodermis (collagen I mixed with HDF) was first lay-
ered by Matrigel™ mixed with DPC; over this, an ORSK cell suspension was lay-
ered 24 hours later. In the “mixed sandwich” (Fig. 6C) a mixture of Matrigel™, 
DPC, and ORSK was placed on top of a pseudodermis. Since proliferation and dif-
ferentiation of most skin cells, especially of NHEK, are strongly affected by the 
presence of serum components and the calcium concentration in the culture me-
dium6,11,19,51,137,180,188,189,193, we investigated the effects of serum withdrawal and of 
switching from a high to a low calcium concentration in the culture media on the 
characteristics of both systems. Both systems were then compared by histology, 
quantitative histomorphometry and/or immunohistology with respect to overall 
morphology, arrangement and number of epithelial cell clusters, ORSK and DPC 
proliferation or apoptosis, CK6 or Versican expression. 
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Figure 6. Schematic drawing of previously described organotypic co-cultures and the newly devel-
oped systems. 
Normal human epidermal keratinocytes (NHEK) were used in previous organotypic 3D systems layered above 
collagen I mixed with human dermal fibroblasts (HDF). Also only collagen I gels or collagen I mixed with HDF 
or dermal papilla fibroblasts (DPC) were used and covered with various cell and matrix mixtures. MatrigelTM 
mixed with NHEK or outer root sheath keratinocytes (ORSK), and MatrigelTM mixed with epithelial and mesen-
chymal cell populations NHEK and HDF or ORSK and DPC was used  (panel A) 101,193. All these 3D systems 
were cultured at the air-liquid interface. Our new “layered sandwich” was prepared from collagen I mixed with 
HDF (pseudodermis) and layered firstly with MatrigelTM with DPC above and after with ORSK on the top 
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(panel B). In the “mixed sandwich”, we used pseudodermis (collagen I with HDF) layered above with the mix-
ture of DPC and ORSK in MatrigelTM matrix (panel C). 
7.1.2 Results 
 
The „mixed” and the „layered” 3D systems meet all basic criteria for „follicu-
loid” organotypic systems that imitate human hair follicle epithelial-
mesenchymal interactions. 
 
Both the „mixed” and the „layered” folliculoid 3D systems are the first or-
ganotypic assays that meet all six minimal criteria proposed above that any in vitro 
organotypic assay system should fulfill, which aims at imitating basic principles of 
epithelial-mesenchymal interactions in the human HF: 
 
1. ORSK and DPC are in physical contact under 3D conditions (see Fig. 7B) . 
2. The use of Matrigel™, which contains laminin, collagen IV, heparan sulfate pro-
teoglycans, entactin, nidogen (BD Bioscience product specification sheet), en-
sures that the extracellular matrix, through which ORSK-DPC interactions oc-
curr, also contains basement membrane components. 
3. Both 3D systems allow the epithelial HF cells (here: ORSK) to form spheroid 
cell aggregates, thus at least vaguely mimicking the compact epithelial tissue 
compartments as they occur in the outer and inner root sheaths or the hair ma-
trix of the HF in vivo (Fig. 7A, B). 
4. The epithelial HF cells (ORSK) show substantial proliferation (Fig. 8A), HF-
type keratinization (i.e. CK6 expression; Fig. 9) and a low level of apoptosis 
(Fig. 8C). Instead, as required, the HF mesenchymal cells (DPC) show minimal 
proliferation (Fig. 8B) and minimal apoptosis (Fig. 8D), thus approximating the 
characteristically minimal basal rate of proliferation of the follicular dermal pa-
pilla and the virtual absence of fibroblast apoptosis, in vivo. In addition, the 
DPC maintain in both sandwich systems their characteristic secretory activities 
that distinguish HF fibroblasts from interfollicular dermal fibroblasts (i.e. they 
display strong expression of the large proteoglycan, versican [Fig. 10A]). 
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5. As in vivo, the interaction of ORSK and DPC is supported by a fibroblast-
contracted collagen type I gel that resembles the interfollicular dermis         
(Fig. 7A). 
6. The “folliculoid” 3D systems can be successfully cultured under continuously 
submerged culture conditions. 
 
In both the “layered” and “mixed” folliculoid systems, the ORSK formed 
spheroid epithelial cell aggregates which retained their characteristic keratin 
expression pattern (Fig. 9A), while the DPC were cumulated in clusters and 
remained versican+ (Fig. 10A). In the following, differences between the two dif-
ferent “folliculoid” systems and between the use of three different media (high/low 
calcium, presence/absence of serum) are delineated. 
 
 
The “mixed” sandwich model generates outer root sheath keratinocytes ag-
gregates with a smaller diameter, while the outer root sheat keratinocytes 
and dermal papilla cell numbers are higher than in the “layered” sandwich 
model.  
 
 As revealed by HE staining of the histological sections of the 3D systems, 
significant differences among the morphological characteristics of the two cultures 
were found (Fig. 7A,B). Although, in both systems, the ORS cells formed multicel-
lular spheroid clusters (similarly to those described by Limat 101), the spheroids in 
the “layered” sandwich entered much less to the Matrigel™, whereas the ORS 
clusters were well distributed in the Matrigel™ matrix of the “mixed” sandwich.  
 
 In addition, the “layered” system, in media 1 (high Ca with FC) and 2 (high 
Ca without FC),  showed much larger spheroids than in medium 3 (low Ca without 
FC) (Fig.11): the mean diameter of the multicellular aggregations was 0.522 ± 
0.12 mm in medium 1; 0.44 ± 0.21 mm in medium 2; and 0.183 ± 0.08 mm in me-
dium 3 (all expressed as mean ± SD). In the “mixed” sandwich, however, when 
compared to results with the “layered” sandwich (Fig.11), much smaller clusters 
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were formed in media 1 (0.313 ± 0.13 mm, mean ± SD) and 2 (0.239 ± 0.078 mm, 
mean ± SD) but not in medium 3 (0.206 ± 0.041 mm, mean ± SD), indicating that 
modifications of the culture media affected the morphological characteristics of the 
“layered” system much stronger than that of the “mixed” sandwich. Although this 
was not evaluated quantitatively, high calcium conditions appeared to favor corni-
fication in the ORSK aggregates in the “layered” sandwich assay (see Fig. 9A, left 
panel) 
 
As microscopic comparison of immunofluorescent pictures of different 
sandwiches revealed no noticeable differences among various culture media, the 
number of CK6 and Versican positive cells were measured in the multicellular 
clusters. As seen in Fig. 12A, the number of (CK6+) ORSK in media 2 and 3 was 
much greater in the “mixed” sandwich than in the “layered” one. Furthermore, in 
the “layered” co-culture, but not in the “mixed” one, the withdrawal of serum and/or 
the decrease in calcium content of the culture media remarkably suppressed the 
number of cells. In addition, the number of (versican+) DPC was also much 
greater in the „mixed” sandwich in all three media applied (Fig. 12B). However, we 
found significantly suppressed DPC numbers in medium 3 in both sandwiches. 
 
 
Outer root sheat keratinocytes proliferate better in the „mixed” than in the 
„layered” sandwich system, regardless of the calcium or serum content of 
the media, whereas the proliferation and apoptosis of dermal papilla cells, in 
both sandwich systems, strongly depends on the amount of serum and cal-
cium in culture media. 
 
The proliferation and apoptotic properties of ORSK and DPC (Fig. 8) after 
14 days in the culture were compared. In medium 1 (high- calcium medium, pres-
ence of FC), the growth properties of ORSK were significantly greater in the 
„mixed” sandwich compared to the “layered” one, as revealed by immunohisto-
chemical detection of the proliferation marker Ki67 and by determining the per-
centage of Ki67 and CK6 positive cells (Fig. 8A). In contrast, such differences 
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were not observed in the case of DPC; namely, in medium 1, the percentage of 
Ki67 and versican positive cells were very similar both in the „layered” and in the 
„mixed” systems (Fig. 8B). 
 
In medium 2 ( high-calcium medium without FC), the expression of Ki67 in 
CK6 positive cells behaved very similarly to that seen in sandwiches cultured in 
medium 1 (Fig. 8A). Cellular proliferation of ORSK in the „mixed” sandwich signifi-
cantly increased when compared to the „layered” one. However, although some 
non-significant tendencies for higher proliferation in serum-free medium could be 
observed, we found no marked differences among data obtained in the two media 
in either sandwich. 
 
In contrast, the Ki67 expression in DPC was remarkably affected by the se-
rum content of the medium (Fig. 8B). In both sandwiches, the withdrawal of serum 
significantly reduced the percentage of Ki67 in Versican positive cells suggesting 
that the presence of serum is a growth-promoting factor for the proliferation of 
DPC. Furthermore, we observed a significantly decreased Ki67 expression in DPC 
(cultured in medium 2) in the „mixed” sandwich compared to the „layered” one. 
 
The behavior of cells in the sandwiches in low calcium concentration and 
serum-free medium (medium 3) were also examined. Essentially, very similar find-
ings were observed for both the ORSK and DPC with those in the experiments 
performed in medium 2 (Fig. 8A and B). Namely, cellular proliferation of ORSK in 
the „mixed” sandwich significantly increased compared to that seen in the „lay-
ered” system. Moreover, no major differences were found among the effects of dif-
ferent media in either sandwich. In addition, similarly to that seen in medium 2, 
significantly less Ki67 expression in versican+ DPC was identified in the low cal-
cium medium 3 in both sandwiches than found in medium 1. 
 
Interestingly, the proliferation of ORSK was not affected by the serum or 
calcium content of the media in both systems, similarly to findings observed with 
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organotypic co-cultures with NHEK193. However, it is important to note that ORSK 
proliferated better in the „mixed” sandwich than in the „layered” cultures (Fig. 8A). 
 
 Apoptosis of DPC is highest in the presence of serum and/or under high 
calcium conditions, while the apoptosis of both ORSK and DPC is lowest in the 
“mixed” sandwich model cultured in serum-free, low calcium medium  
 
The percentage of TUNEL positive cells in ORSK growing in the „layered” 
3D system was almost identical in the three different solutions (Fig. 8C). Similarly 
to these data, no differences among the apoptosis of ORSK growing in the „mixed” 
sandwich in the high calcium concentration media (medium 1 and 2) were ob-
served. However, in contrast to the above data, ORS cells of the „mixed” sandwich 
showed an extremely suppressed apoptosis in the low calcium serum-free medium 
3 (Fig. 8C). 
 
In the „layered” sandwich, the percentage of TUNEL positive DPC cells in 
the different media changed very similarly to that found with the expression of the 
proliferation marker (seen in Fig. 8B). Namely, the highest level of apoptosis was 
observed in medium 1 (high calcium, presence of serum), whereas the decrease 
of calcium concentration in medium 3 significantly (and the withdrawal of serum 
markedly yet not significantly) suppressed the number of TUNEL positive cells 
(Fig. 8D). In the „mixed” sandwich, the highest level of DPC apoptosis was also 
observed in medium 1, which, similarly to that seen in the „layered” system, 
slightly decreased by the removal of serum in medium 2, which however was re-
markably suppressed when calcium was decreased in medium 3. 
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Figure 7.  Histology (hematoxylin-eosin stain) of spheroid structures in the “layered” and “mixed” sys-
tems cultured in various media. 
Panel A. Different 3D co-cultured “layered” and “mixed” systems were established and cultured submerged in 
medium 1 (high Ca concentration, with Fetal Clone, + FC), in medium 2 (high Ca concentration, without Fetal 
Clone, - FC), or in medium 3 (low Ca concentration, without Fetal Clone, - FC). Panel B. Outer root sheath 
keratinocytes (O) and dermal papilla fibroblasts (D) are in physical contact under 3D conditions. Original mag-
nification, 100x for panel A, 200x for panel B. 
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Figure 8.  Quantitative analysis of proliferation and apoptosis of ORSK and DPC in the two systems 
cultured in various media for 14 days. 
Series of double immunolabeling was performed to define the number of Ki67 positive (proliferating, panel A 
and B) and TUNEL positive (apoptotic, panel C and D) cells in cytokeratin-6 (CK6) expressing outer root 
sheath keratinoctyes (ORSK, panel A and C) or versican expressing dermal papilla fibroblasts (DPC, panel B 
and D) cells, as described in „Materials and Methods“ section. The numbers of double positive cells 
(Ki67+/CK6+, TUNEL+/CK6+, Ki67+/versican+, TUNEL+/versican+) in each group were determined, and ex-
pressed as a percentage of total number of cells expressing the respective marker for ORSK (CK6+) or for 
DPC (versican+). All data are shown as mean ± SD. Asterisks mark significant (p < 0.05) differences. 
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Figure 9.  Immunohistochemical identification of CK6 expression in the two systems cultured in vari-
ous media. 
Cryosections of 3D co-cultures (panel A) and human hair follicle, which served as a positive control (panel B), 
were air dried, fixed in acetone, and then probed with a mouse anti-human cytokeratin-6 (CK6) to identify 
outer root sheath keratinocytes. Immunofluorescent labeling was employed using a FITC-conjugated secon-
dary antibody (green fluorescence) whereas cell nuclei were labeled using DAPI (blue fluorescence). Original 
magnification, 250x for panel A, 100x for panel B. All figures are representatives of at least three determina-
tions with similar results. 
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Figure 10.  Immunohistochemical identification of versican expression in the two systems cultured in 
various media. 
Cryosections of 3D co-cultures (panel A) and human hair follicle, which served as a positive control (panel B), 
were air dried, fixed in acetone, and then probed with a mouse anti-human versican to identify dermal papilla 
fibroblasts. Immunofluorescent labeling was employed using a rhodamine-conjugated secondary antibody (red 
fluorescence) whereas cell nuclei were labeled using DAPI (blue fluorescence). Original magnification, 250x 
for panel A, 100x for panel B. All figures are representatives of at least three determinations with similar re-
sults. 
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Figure 11. Quantitative analysis of the averaged diameter of multicellular spheroid clusters in the two 
systems cultured in various media. 
On the HE stained histological sections, using a calibrated ocular eye-piece of a light-microscope, the largest 
diameter of the spheroids was measured on at least 75 clusters per group. The values were then averaged 
and were expressed as mean ± SD. Statistical analysis was performed using Mann-Whitney non-parametric 
test. Two types of statistical comparison were carried out. First, to reveal the differences between the different 
media within the given co-culture, the values obtained in the 3 different media were compared to one another 
either in the “layered” or in the “mixed” cultures. Then, to assess differences between the two co-cultures, val-
ues obtained in the given culturing medium in the “layered” sandwich were compared to those of the “mixed” 
one cultured in the same medium. Asterisks mark significant (p < 0.05) differences. 
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Figure 12.  Quantitative analysis of the number of CK6 or versican positive cells of multicellular sphe-
roid clusters in the two systems cultured in various media. 
The number of cytokeratin-6 (CK6) (panel A) or versican (panel B) positive cells in clusters was determined by 
visual counting of cells on immunolabeled sections of 3D systems. Values were then averaged and shown as 
mean ± SD. Asterisks mark significant (p < 0.05) differences. 
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7.1.3 Discussion 
 
The aim of the present study was to develop the first “folliculoid” 3D system 
that meets - as pragmatically and as economically as possible - six defined mini-
mal criteria of a useful human “folliculoid” organotypic assay for studying and dis-
secting epithelial-mesenchymal interactions that approximate those occurring in a 
human HF. As shown in Figs. 7-12, both the “mixed” and the “layered” sandwich 
systems meet this criteria. In this respect the “mixed” system (= pseudodermis 
plus one layer of  mixture of ORSK and DPC in MatrigelTM), cultured under low 
calcium and serum-free conditions, was identified as optimal.  
 
Simultaneously, the investigation was carried out in order to establish well-
defined basic parameters for a qualitative and quantitative assessment of the 
modulatory effects of a given test agent. By assessing the effect of different media 
with high/low calcium conditions and/or absence/presence of serum on these pa-
rameters (number and diameter of ORSK aggregates, Ki67+ , TUNEL+, CK6+, 
Versican+ cells), it was shown that both “folliculoid” sandwich systems can serve 
as robust screening systems. These assays now can be applied to the testing of 
standard hair growth-modulatory agents in the human system (e.g. cyclosporin A, 
HGF, minoxidil, IGF-1, steroid hormones 122,145) in order to explore whether recog-
nized hair growth stimulators really upregulate e.g. ORSK proliferation and/or DPC 
secretion of hair follicle morphogens in the sandwich assays reported.  
 
In both sandwich systems (“mixed”, “layered”), the ORSK appeared to be-
have essentially “in vivo-like” since they formed CK6+ spheroids or cells aggre-
gates (ORSK) (Fig. 7). However, epidermal-like stratification was not seen in the 
organotypic co-cultures of ORSK, in contrast to what Limat et al. had described in 
his co-culture systems at the air-liquid interface 100,104 (Fig. 6A). This difference 
can be interpreted as a reflection of the – more in vivo-like - continuous sub-
merged culture conditions used in this study. It has also been shown that ORSK 
form epidermis-like stratified epithelia, when layered to matrices without 
DPC100,104. The “layered” 3D system investigated herein showed that the presence 
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of an intermediary layer of MatrigelTM-embedded DPC induced the overlying 
ORSK to aggregate in clusters, rather than into an epidermis-like structure (Fig. 
7A left side).This confirms the dominant role of DPC in driving cultured human 
ORSK towards a more hair follicle-like differentiation pathway. 
 
It has been documented extensively that the serum and/or calcium content 
of the culture medium exerts profound influences on the morphological and func-
tional characteristics of NHEK-based organotypic co-cultures 
6,11,19,51,137,180,188,189,193. This study however provides the first systematic compari-
son of various media with differences in calcium concentration and/or serum con-
tent on basic test parameters in human “folliculoid” organotypic cultures. This 
comparison suggests that the “mixed” system (= pseudodermis plus one layer of 
mixture of ORSK and DPC co-cultured in MatrigelTM), comes closest to meeting 
the defined criteria, if the “folliculoids” are cultured under low calcium- and serum-
free conditions. As one would demand of an optimal in vitro-system that imitates 
human HF epithelial-mesenchymal interactions as closely as can reasonably be 
expected in vitro, DPC show only negligible apoptosis and minimal proliferation 
under these conditions, while the ORSK proliferate at comparatively very high lev-
els, while displaying minimal apoptosis (Fig. 8).  
 
This defined optimal growth conditions for a human “folliculoid” 3D system 
should greatly facilitate further optimization efforts towards the development of 
continuously improved organotypic systems that mimic the in vivo situation in the 
human HF. 
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7.2  Experimental Part II - Microsphere system 
 
Development of a Novel Human Folliculoid Microsphere Assay as Screening 
and Discovery Tool for Basic and Applied Hair Research. 
 
7.2.1 Introduction 
 
Previously, we have defined basic criteria that all hair biology-related or-
ganotypic systems should meet in order to support the claim that they mimic the in 
vivo situation as closely as possible64. Briefly, these criteria are:  
 
1. Outer root sheath keratinocytes (ORSK) and follicular dermal papilla fibro-
blasts (DPC) should be physically interacting. 
2.  The extracellular matrix through which this occurs should also contain 
basement membrane components. 
3. The epithelial HF cells should form cell aggregates. 
4. Epithelial HF cells should show substantial proliferation as well as HF-type 
keratinization and a low level of apoptosis; mesenchymal cells should show 
minimal proliferation and minimal apoptosis and should display specialized, 
HF-type secretory activities,  
5. and these organotypic systems should be cultured under continuously 
submerged culture conditions in well defined media (i.e. under serum-free 
conditions and with a defined concentration of calcium ions). 
 
Using these criteria, two novel folliculoid organotypic systems64 “layered 
sandwich” and “mixed sandwich” have been developed. Comparison of these sys-
tems suggest that the “mixed sandwich” system cultivated under continuously 
submerged condition in serum-free, low calcium medium meets all basic criteria 
and offers several advantages over previously available assays64,101,104. 
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However, so far these assays are still very laborious and time-consuming, 
and only a very limited number of such ”sandwiches” can be generated at any 
time, thus hampering the usefulness of this system as a higher-throughput screen-
ing tool. Therefore, the goal of this study was to develop a novel, more easy-to-
handle in vitro-assay which also: 
 
1. requires lower cell numbers (especially of DPC) per test unit; 
2. is easier and faster to prepare than previously published 3D folliculoid sys-
tems; 
3. is well-reproducible with a large number of test units; 
4. is less expensive; 
5. responds to recognized hair growth-modulatory drugs in a manner that best 
approximates the clinical response to these agents; and 
6. functions as a discovery tool for identifying new target genes and/or their 
protein products for candidate hair growth-modulatory agents. 
 
This study describes a novel and pragmatic human folliculoid microsphere 
(HFM) assay that meets all the basic and modified prerequisites for in vitro higher-
throughput screening systems for pre-clinical candidate hair drug screening. 
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7.2.2 Results 
 
Characteristics of interacting human HF-derived epithelial and mesenchymal 
cells in the HFM. 
 
First the characteristics of cells within the HFM system were investigated. 
We found that ORSK and DPC, forming spheroid cell aggregates, were in close 
physical contact in the HFM (Fig. 13B-C) and that the employed extracellular ma-
trix indeed contained basement membrane components such as fibronectin (Fig. 
13D-E). In addition, epithelial ORSK showed HF-type keratinization (i.e. CK6 ex-
pression; Fig. 13G-H, K, L), substantial proliferation (i.e. Ki67 expression in the 
CK6 positive cells, Fig. 13K and 14A), and a low level of apoptosis (number of 
TUNEL positive ORSK, Fig. 13L and 14C). Instead, the HF mesenchymal DPC 
exhibited minimal proliferation and apoptosis (Fig. 13M and N, Fig. 14B and D) 
but maintained their characteristic, specific secretory activity, i.e., they displayed 
strong expression of the large proteoglycan versican191 (Fig. 13 I-J, M, N). 
 
In most of experiments, in accordance with the findings in the previously 
developed “sandwich” 3D systems 64, serum-free culturing media that contained 
low concentrations of calcium (0.15 mM) was used. However, the biological fea-
tures of the cells in the HFM cultured in high calcium solutions were also deter-
mined. During the 10 day culture period no difference in proliferation and apop-
tosis of ORSK in the two different media was found (Fig. 14A and C). In contrast, 
both the proliferation and the apoptosis of DPC significantly increased in high-Ca 
medium compared to low-Ca solution (Fig. 14B and D). 
 
Furthermore, the processes of possible necrosis were also investigated by 
measuring the LDH release during the 10 day culture period in low-Ca media. The 
maximum amount of LDH (20 U/L) was seen on day 3 when the system was (most 
probably) still under the “stress” caused by the preparation of the HFM. On days 7 
and 10, the LDH levels returned to normal, which suggests a full recovery of the 
cells in the HFM (Fig. 14E). 
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It was therefore concluded, that the HFM meet all the basic criteria of an 
organotypic folliculoid system and that they can be successfully cultivated under 
continuously submerged culture conditions (most efficiently in low-Ca media) re-
maining vital for at least 10 days. 
 
Hair folliculoid HFM show several advantages over folliculoid “sandwich” 
systems. 
 
Comparison of the current data with those obtained by previous “sandwich” 
systems also revealed that the preparation of micropheres: 
 
1. requires lower number, yet higher density of cells (especially DPC) per test 
unit. Although the density of ORSK was essentially the same (1 x 106 cells 
mL-1) both in the “sandwich” and HFM systems, double DPC density (2 x 
106 cells mL-1) in the HFM was achieved. In addition, the remarkably higher 
number of test units that can be obtained using 1 ml of cell suspension in 
the HFM system (i.e. 30-50 HFM compared to the 10 “sandwiches”) also 
suggests that the same amount of test units can be prepared using much 
fewer cells; 
2. is easier and faster. The average time to prepare the HFM was only a few 
hours compared to the approximately 5 day-long preparation time at best 
needed for any of the two “sandwich” systems presented before64  
3. is easily repeatable with higher number of test units, which allows a higher 
degree of standardization and greatly facilitates automation. In addition, the 
HFM system allows for the preparation of test units with variable sizes, de-
pending on specific experimental needs; and  
4. due to the dramatic decrease in culture time and consumables, is less ex-
pensive. 
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Negative regulators of HF growth differentially inhibit proliferation and in-
duce apoptosis in cells growing in the HFM. 
 
In the next phase of these experiments, the novel HFM system was as-
sessed in terms of whether is also suitable to analyze the actions of recognized 
hair growth-modulatory drugs (the effects of all agents examined are summarized 
in Table 1 and 2). At first the effects of the potent HF growth inhibitory agents 
were investigated, i.e. 10-6M tretinoin 50, 25 ng/ml transforming growth factor-β2 
(TGFβ2) 69,192, and 10-7 M corticotropin-releasing hormone (CRH) 78,187 (Table 1). 
As expected, all agents significantly decreased the number of Ki67 positive (hence 
proliferating) cells in the CK6 positive ORSK (Fig. 15A, 16A, Table 1A). In addi-
tion, tretinoin (Fig. 15C) and TGFβ2 (Fig. 16C), but not CRH (Table 1B), in-
creased the number of TUNEL positive ORSK, suggesting stimulation of apop-
tosis. Furthermore, TGFβ2 (Fig. 16B) suppressed the number of Ki67 positive 
DPC, whereas the other two agents did not affect the proliferation of these cells 
(Fig. 15B and Table 1A). Finally, tretinoin (Fig. 15D) and TGFβ2 (Fig. 16D) 
stimulated apoptosis in DPC as well, while CRH, similar to its lack of action as 
seen on ORSK, did not affect the process (Table 1B). 
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Table 1. The effect of hair growth inhibitors on proliferation (a) and apoptosis (b) of ORSK and DPC in 
the HFM 
 
 
(a)  Effects of hair growth inhibitors on proliferation 
 
  
 
Ki67-positive cells in ORS  
(% of control)  
 
Ki67-positive cells in DPC  
(% of control)  
Days of     
culture  Day 7  Day 10  Day 7  Day 10  
Tretinoin 40.9 23 ↓**  34.4 26 ↓** 100.5 23 98.2 27 
TGF 2  48.4 19 ↓* 37.7 23 ↓** 22.7 14 ↓**   26.4 27 ↓**   
CRH 61.3 19 ↓* 62.8 15 ↓* 92.6 37 93.1 38 
          
 
(b)  Effects of hair growth inhibitors on apoptosis  
 
  
 
TUNEL-positive cells in ORS    
(% of control)  
 
TUNEL-positive cells in DPC    
(% of control)  
Tretinoin 176.2 22 ↑*  195.8 24 ↑*   105.6 29 226.8 37   ↑** 
TGF 2  185.4 24 ↑*   245.5 23 ↑**  188.1 27 ↑**   225.23 36 ↑** 
CRH 115.8 23           91.6 32 96.9 29 91.4 36 
     
 
CRH, corticotropin-releasing hormone; TGF 2, transforming growth factor- 2. 
 
Series of double immunolabeling was performed to define the number of Ki67-positive (proliferating, a) and 
TUNEL-positive (apoptotic, b) cells in CK6 expressing outer root sheath keratinocytes (ORSK) or versican 
expressing dermal papilla fibroblasts (DPC). The numbers of double positive cells (Ki67+/CK6+, 
TUNEL+/CK6+, Ki67+/versican+, TUNEL+/versican+) in each group were determined, and expressed as 
mean SD values as a percentage of the control (non-treated) samples regarded as 100%. All data are shown 
as mean value SD. Asterisks mark significant (* p<0.05; ** p<0.01; ↑ increase; ↓decrease) differences. 
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Table 2. The effect of hair growth stimulators on proliferation (a) and apoptosis (b) of ORSK and DPC 
in the HFM 
 
(a)  Effects of hair growth stimulators on proliferation  
 
  
 
Ki67-positive cells in ORS  
(% of control)  
 
Ki67-positive cells in DPC 
(% of control)  
Days of      
culture  Day 7  Day 10  Day 7  Day 10  
IGF-I 192.8 37 ↑*  215.5 28 ↑**  266.9 38 ↑**   360.6 42 ↑**   
Calcitriol 193.7 26 ↑** 198.1 30 ↑**  220.9 21 ↑**   117.5 27 
CsA, low Ca 170.8 26 ↑*  195.4 29 ↑**  212.8 21 ↑**   252.9 32 ↑**   
CsA, high Ca 124.7 38 116.3 21 115.6 19 123.8 29 
HGF, low Ca 197.5 33 ↑*  169.5 28 ↑*  106.7 34 176.3 30 ↑*  
HGF, high Ca 167.1 19 ↑*  196.9 21 ↑**  116.8 22 94.1 26 
 
(b)  Effects of hair growth stimulators on apoptosis  
 
  
 
TUNEL-positive cells in ORS 
(% of control)  
 
TUNEL-positive cells in DPC 
(% of control)  
IGF-I 87.3 30 129.2 55 97.6 31 94.6 27 
Calcitriol 127.5 39 112.7 23 121.5 27 125.9 28 
CsA, low Ca 117.9 27 123.9 33 93.5 20 114.9 28 
CsA, high Ca 116.01 31 215.7 37 ↑*  119.39 64 118.42 62 
HGF, low Ca 86.8 31 92.3 22 111.2 26 84.7 29 
HGF, high Ca 90.9 19 90.4 18 91.8 24 93.3 16 
  
CsA, cyclosporin A; HGF, hepatocyte growth factor; IGF-1, insulin-like growth factor 1. 
 
Series of double immunolabeling was performed to define the number of Ki67-positive (proliferating, a) and 
TUNEL-positive (apoptotic, b) cells in CK6 expressing outer root sheath keratinocytes (ORSK) or versican 
expressing dermal papilla fibroblasts (DPC). The numbers of double positive cells (Ki67+/CK6+, 
TUNEL+/CK6+, Ki67+/versican+, TUNEL+/versican+) in each group were determined, and expressed as 
mean value SD values as a percentage of the control (non-treated) samples regarded as 100%. All data are 
shown as mean value SD. Asterisks mark significant (* p<0.05; ** p<0.01; ↑ increase; ↓decrease) differences. 
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Positive regulators of HF growth stimulate proliferation of ORSK and DPC in 
the HFM without affecting apoptosis. 
 
The effect of recognized HF growth-promoting agents was investigated 
next, i.e. insulin-like growth factor-I (IGF-I) 160, 1α,25 dihydroxyvitamin D3 
(1,25(OH)2D3, calcitriol) 63,183,202, cyclosporin A (CsA) 91, and hepatocyte growth 
factor (HGF)83 (Table 2). Applications of 100 ng/ml of IGF-I, 10-8 M calcitriol, 10 
ng/ml CsA, and 10 ng/ml HGF resulted in very similar modifications in the func-
tions of the cells in the microspheres (Table 2). Namely, all agents increased pro-
liferation (elevated the number of Ki67 positive cells) both in the ORSK (Fig. 17A 
and C, Fig. 18A and C) and DPC (Fig. 17B and D, Fig. 18B and D) populations 
without exerting any measurable effect on apoptosis of these cells (Table 2B). 
 
The effects of CsA and HGF are modified by the alteration in the calcium 
concentration of the culture media. 
 
The above data, as mentioned before, was obtained in experiments where 
low-Ca media was used to culture the HFM. Previous studies, however, suggest 
that the effects of CsA 197 and HGF 181 on proliferation of keratinocytes are 
strongly affected by the calcium content within the culture media. Therefore, these 
molecules were also tested on HFM cultured under high-Ca conditions. In marked 
contrast to data obtained in the low-calcium medium, 10 ng/ml CsA in high-calcium 
solution did not significantly stimulate the proliferation of ORSK and DPC (Table 
2A) but, intriguingly, induced apoptosis in the ORSK (Table 2B). The effects of 
HGF (10 ng/ml) to stimulate proliferation of ORSK (Table 2A) and not to modify 
apoptosis of ORSK and DPC (Table 2B) were essentially the same in the two me-
dia. However, contrary to the low-Ca data, HGF was unable to promote prolifera-
tion of DPC in HFM cultured in high-Ca solution (Table 2A). These findings unam-
biguously argue for the careful selection of which calcium concentration to use for 
the culture media. 
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The HFM are suitable for the investigation of protein and gene expression of 
cytokines and growth factors involved in HF biology. 
 
The question whether the HFM system can operate as a discovery tool for 
identifying new target genes (and their protein products) for candidate hair growth 
modulatory agents was investigated as well. Therefore the expression of such bio-
logical markers (on protein and mRNA level) in the HFM, which were previously 
described as important regulators in HF biology in vivo were measured. Using im-
munofluorescence, the expression of TGFβ2 (negative regulator of hair growth) 
and stem cell factor (SCF, hair growth stimulator 195,153) in the cells of the micro-
spheres could clearly be shown (Fig. 19A-D). In addition, employing RT-PCR on 
RNA isolated from the HFM, we could also detect the mRNA transcript of these 
molecules (Fig. 19E-F). 
 
Positive and negative regulators of hair growth may not only directly affect 
the biological processes of the cells of the HF but, very often, significantly modify 
the complex cytokine/growth factor network of the mini-organ. Investigation, using 
RT-PCR, was used in order to highlight the effects of some of those hair growth-
modulatory agents on the expression of endogenous TGFβ2 and SCF which, 
when applied “exogenously”, significantly affected proliferation and apoptosis of 
cells in the HFM (see above). 
 
As shown in Fig. 19G, 25 ng/ml “exogenous” growth inhibitor TGFβ2 (Fig. 
16 and Table 1) remarkably up-regulated the gene expression of “endogenous” 
TGFβ2 but did not affect the expression of SCF. Partly similar to these findings, 
10-6M tretinoin (another negative regulator, Fig. 15 and Table 1) also significantly 
increased the level of TGFβ2 mRNA transcripts; however, in contrast to the effect 
of “exogenous” TGFβ2, it also significantly decreased the expression of the 
growth-promoter SCF. Moreover, it was shown that the CsA (a positive regulator 
of HF growth, Fig. 18A and B), significantly suppressed the expression of the 
growth-inhibitory TGFβ2 without affecting the level of SCF. 
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The HFM are also suitable for the investigation of global gene expression 
profiles. 
 
Finally, the novel model system was further analyzed in order to see 
whether it could determine changes of global gene expression profiles upon ex-
perimental manipulations. Therefore, in a pilot study, HFM were treated with cer-
tain hair growth stimulatory agents (such as HGF, calcitriol, IGF-I, and 17β Estra-
diol)24,133,162,198 for 7 days, then a Micro-Array analysis that represented the whole 
human genome (Agilent®, 44K, G4112A) was performed to follow gene expres-
sion alterations. As seen in Table 3 (showing changes of only selected genes), 
treatment of the HFM with recognized growth stimulators induced remarkable 
changes in the expressions of certain genes with potential roles in regulation of HF 
growth, development, and cycling. Hence, although these preliminary findings re-
main to be repeated and confirmed by quantitative “real-time” PCR, our data (in 
accordance with the above findings, see Fig. 19) further indicate that the novel 
HFM system was indeed a suitable model for studying HF biology since, similarly 
to those seen in the HF, agents affecting proliferation and apoptosis of cells in the 
HFM may also significantly alter the global gene (and protein) expression profile of 
e.g. molecules of cytokine and growth factor signaling. 
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Table 3.  Alterations in the expression of selected genes expressed in HFM after 7 days of incubation 
with various recognized hair growth stimulators (HGF, calcitriol, IGF-I, 17-ß estradiol).  
 
The genes shown have been selected on the basis of established biological functions, relevant expression 
levels or relatedness to factors known in hair follicle biology.  
 
HGF (10 ng/ml) 
 
Gene Expression 
change 
(fold) 
Recognized function 
in HF biology 
Comments Selected 
references
Ephrin-A5 
(NM_001962) 
↑, 6.5 Ephrin A3 gene was 
down-regulated in 
androgenic alopecia. In 
addition, ephrin A3 
raised the proliferation 
rate of the outer root 
sheath keratinocytes 
(ORSK) and induced 
gene expression in 
acidic hair keratin 3-II 
suggesting that ephrin 
A3 functions as hair 
growth promoting factor 
in the hair cycle. 
No information on 
Ephrin-A5 in skin 
available. 
 
126  
Insulin-like 
growth factor-II 
mRNA-binding 
protein-1 
(AK022617) 
↑, 3.5 Not known.  
However, IGF is a 
potent hair growth 
stimulator. 
Implicated in mRNA 
localization, turnover, 
and translational 
control. Stimulates 
cell proliferation. In 
deficient mice, sig-
nificant retardation of 
growth is observed. 
62,99  
Lysyl oxidase 
(NM_002317) 
↑, 3.1 Progressive hair loss in 
rough coat (rc) mice 
which show reduced ly-
syl oxidase-like protein. 
Extracellular matrix 
regulator. 
65  
Retinol binding 
protein-4 
(NM_006744) 
 
↑, 2.5 Stimulation of RA recep-
tors inhibits hair growth. 
Potential hair growth 
inhibitor. 
50  
Sex hormone-
binding  globulin 
(SHBG) 
(NM_001040) 
 
↑, 2.2 Decreased protein lev-
els in patients with  
isolated hirsutism. 
Limits the levels of 
circulating free sex 
hormones (especially 
androgens). 
200  
Ectodysplasin A 
(NM_001399) 
 
↑, 2.2 Critical for normal HF 
development. 
 184,185  
Angiopoietin-2 
(NM_001040) 
↑, 2.1 Modulation of perifollicu-
lar vasculation (hair 
cycle-dependent vascu-
lar remodeling). 
 147  
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Calcitriol (10-8 M) 
 
Gene Expression 
change 
(fold) 
Recognized function in 
HF biology 
Comments Selected 
references
Delta- and 
Notch-like      
Epidermal 
Growth Factor-
related receptor 
(NM_139072) 
↑, 4,9 The Notch pathway (and 
its receptor, Delta-1) is a 
central regulator of hair 
follicle growth and       
development and inter-
cellular communication 
mechanisms. 
 168  
Interleukin 1    
receptor, type II 
(NM_004633) 
 
↑, 2.9 Unknown. Antagonizes           
interleukin 1 activity. 
71  
Insulin-like 
growth factor 
binding protein-3
(S56205) 
 
↑, 2.1 Regulates activity of IGF, 
a potent hair-growth 
stimulator. 
Potential hair growth 
inhibitor. 
68  
Transforming 
growth factor β1 
(NM_000660) 
 
↑, 2.1 Potent hair growth        
inhibitor. 
 69,192  
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IGF-I (100 gn/ml) 
 
Gene Expression 
change 
(fold) 
Recognized function in 
HF biology 
Comments Selected 
references
Growth hormone 
2 
(NM_173841) 
↑, 4.5 Unknown. In peripheral tissues, 
activates the hair 
growth promoting   
insulin-like growth 
factor-I signaling. 
161  
Interleukin 1    
receptor           
antagonist  
(NM_173841) 
 
↑, 4.2 Hair growth promoter by 
inhibition of IL-1. 
 162,163  
Frizzled      
homologue 5 
(NM_003468) 
 
↑, 4.0 The Frizzled gene family 
plays a key role in hair 
follicle development. 
 172  
WNT-6 
(NM_006522) 
↑, 3.1 WNT-receptors are     
important for hair           
development. 
 127,185  
Vascular endo-
thelial growth 
factor 
(AK098750) 
 
 
↑, 3.1 Key promoter of anagen-
associated angiogene-
sis. 
 209  
Keratin 5b 
(NM_173352) 
 
↑, 2.9 Proliferation-associated 
keratin. 
 93,94  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Hair Equivalents
 
 Page 74 of 107 
 
17β Estradiol (10-6 M) 
 
Gene, 
(Accession num-
ber) 
Expression 
change 
(fold) 
Recognized function 
in HF biology 
Comments Selected 
references
Ephrin-A5 
(NM_001962) 
↑, 6.3 Ephrin A3 gene was 
down-regulated in an-
drogenic alopecia. In 
addition, ephrin A3 
raised the proliferation 
rate of ORSK and        
induced gene expres-
sion in acidic hair keratin 
3-II suggesting that eph-
rin A3 functions as hair 
growth promoting factor 
in the hair cycle. 
No information on 
Ephrin-A5 in skin 
available. 
 
126  
Insulin-like 
growth factor-II 
mRNA-binding 
protein-1 
(AK022617) 
↑, 5.5 Not known. However, 
IGF is a potent hair 
growth stimulator. 
Implicated in mRNA 
localization, turnover, 
and translational 
control. Stimulates 
cell proliferation. In 
deficient mice, sig-
nificant retardation of 
growth is observed. 
62,99  
Alkaline        
phosphatase 
(NM_001631) 
↑, 4.3 Expressed in DP, activ-
ity linked to normal hair 
matrix – papilla            
interaction. 
 
Marker of inductive 
potential of DPCs. 
59  
 
Protein kinase 
Cβ1 
(AJ002788) 
↑, 3.6 PKCβ pseudosubstrate 
(as well as the general 
PKC inhibitor 
GF109203X) was shown 
to reduce skin and hair 
pigmentation; hence, it 
is a potential hair growth 
stimulator. 
PKCβ, overex-
pressed in HaCaT 
cells, stimulates pro-
liferation/tumor 
growth, suppresses 
differentiation and 
apoptosis. 
141,142  
Retinol binding 
protein-4 
(NM_006744) 
 
↑, 3.2 Stimulation of RA recep-
tors inhibits hair growth. 
Potential hair growth 
inhibitor. 
50  
Ectodysplasin A 
(NM_001399) 
↑, 2.8 Critical for normal HF 
development. 
 185,186  
Insulin-like 
growth factor 
binding protein 
(NM_004970) 
↑, 2.5 Regulates activity of 
IGF, a potent hair-
growth stimulator. 
Potential hair growth 
inhibitor.  
68  
Sex hormone-
binding globulin 
(NM_001040) 
↑, 2.3 Decreased protein     
levels in patients with  
isolated hirsutism. 
Limits the levels of 
circulating free sex 
hormones (especially 
androgens). 
200  
Glial cell-derived 
neurotrophic fac-
tor 
(NM_000514) 
↑, 2.2 Catagen inhibitor.  16  
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Figure 13. Microscopic photography and histology of the microspheres and the expression of certain 
markers in cells and matrix of the HFM 
 
A) Photomicrographs of HFM in culture at day 10. B-C) Histology of HFM structure (hematoxylin-eosin stain-
ing). ORSK, outer root sheath keratinocytes, DPC, dermal papilla cells. Note the physical contact of ORKS 
and DPC in the HFM. D-E) Expression of fibronectin (as revealed by fluorescein isothiocyanate, FITC, immu-
nostaining, green fluorescence) in the HFM (D) and in microdissected HF used as a positive control (E). F) 
Negative control, the primary antibody was omitted. G-H) Expression of the ORSK marker CK6 (as revealed 
by rhodamine immunostaining, red fluorescence) in the HFM (G) and in microdissected HF (H). I-J) Expres-
sion of the large proteoglycan versican (DPC marker) (as revealed by rhodamine immunostaining, red fluores-
cence) in the HFM (I) and in microdissected HF (L). K-L) Double immunolabeling of the ORSK marker CK6 
(as revealed by rhodamine immunostaining, red fluorescence) with the proliferation marker Ki67 (K) or with 
apoptosis marker TUNEL (L) (in both cases, FITC immunostaining, green fluorescence). M-N) Double immu-
nolabeling of the DPC marker versican (as revealed by rhodamine immunostaining, red fluorescence) with 
proliferation marker Ki67 (M) or with the apoptosis marker TUNEL (N) (in both cases, FITC immunostaining, 
green fluorescence). Original magnification, 40x for A; 100x for B, D-F, H, J; 250x for C, G, I, K-N. For D-N, 
nuclei were counterstained with DAPI (blue fluorescence). 
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Figure 14. Quantitative analysis of proliferation and apoptosis of ORSK and DPC in the HFM cultured 
in various media for 10 days 
 
Series of double immunolabeling was performed to define the number of Ki67 positive (proliferating, A and B) 
and TUNEL positive (apoptotic, C and D) cells in CK6 expressing outer root sheath keratinocytes (ORSK, A 
and C) or versican expressing dermal papilla fibroblasts (DPC, B and D), as described in „Materials and 
Methods“ section. The numbers of double positive cells (Ki67+/CK6+, TUNEL+/CK6+, Ki67+/versican+, 
TUNEL+/versican+) in each group were determined, and expressed as a percentage of total number of cells 
expressing the respective marker for ORSK (CK6+) or for DPC (versican+). All data are shown as mean ± SD. 
Asterisks mark significant (*, p < 0.05) differences. E) Determination of level of the released lactate dehydro-
genase (LDH) during culturing. All data are shown as mean value ± SD. 
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Figure 15. Effects of tretinoin on proliferation and apoptosis of ORSK and DPC in the HFM 
 
HFM were treated with vehicle (Control) or with 10-6 M tretinoin for up to 10 days, then a series of double im-
munolabeling was performed in order to define the number of Ki67 positive (proliferating, A and B) and 
TUNEL positive (apoptotic, C and D) cells in CK6 expressing outer root sheath keratinocytes (ORSK, A and 
C) or versican expressing dermal papilla fibroblasts (DPC, B and D). The numbers of double positive cells 
(Ki67+/CK6+, TUNEL+/CK6+, Ki67+/versican+, TUNEL+/versican+) in each group were determined, and ex-
pressed as a percentage of total number of cells expressing the respective marker for ORSK (CK6+) or for 
DPC (versican+). All data are shown as mean value ± SD. Asterisks mark significant (*p < 0.05; **p < 0.01) 
differences. 
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Figure 16. Effects of TGFβ2 on proliferation and apoptosis of ORSK and DPC in the HFM 
 
HFM were treated with vehicle (Control) or with 25 ng/ml TGFβ2 for up to 10 days, then a series of double 
immunolabeling was performed in order to define the number of Ki67 positive (proliferating, A and B) and 
TUNEL positive (apoptotic, C and D) cells in CK6 expressing outer root sheath keratinocytes (ORSK, A and 
C) or versican expressing dermal papilla fibroblasts (DPC, B and D). The numbers of double positive cells 
(Ki67+/CK6+, TUNEL+/CK6+, Ki67+/versican+, TUNEL+/versican+) in each group were determined, and ex-
pressed as a percentage of total number of cells expressing the respective marker for ORSK (CK6+) or for 
DPC (versican+). All data are shown as mean value ± SD. Asterisks mark significant (*p < 0.05; **p < 0.01) 
differences. 
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Figure 17. Effects of IGF-I and calcitriol on proliferation of ORSK and DPC in the HFM 
 
HFM were treated with vehicle (Control), with 100 ng/ml of IGF-I (A and B), or with 10-8 M calcitriol (C and D) 
for up to 10 days, then a series of double immunolabeling was performed to define the number of Ki67 positive 
(proliferating) cells in CK6 expressing outer root sheath keratinocytes (ORSK, A and C) or versican express-
ing dermal papilla fibroblasts (DPC, B and D). The numbers of double positive cells (Ki67+/CK6+, 
Ki67+/versican+) in each group were determined, and expressed as a percentage of total number of cells ex-
pressing the respective marker for ORSK (CK6+) or for DPC (versican+). All data are shown as mean value ± 
SD. Asterisks mark significant (*p < 0.05; **p < 0.01) differences. 
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Figure 18. Effects of Cyclosporin A and HGF on proliferation of ORSK and DPC in the HFM 
 
HFM were treated with vehicle (Control), with 10 ng/ml Cyclosporin A (A and B), or with 10 ng/ml HGF (C and 
D) for up to 10 days, then a series of double immunolabeling was performed to define the number of Ki67 
positive (proliferating) cells in CK6+ expressing outer root sheath keratinocytes (ORSK, A and C) or versican 
expressing dermal papilla fibroblasts (DPC, B and D). The numbers of double positive cells (Ki67+/CK6+, 
Ki67+/versican+) in each group were determined, and expressed as a percentage of total number of cells ex-
pressing the respective marker for ORSK (CK6+) or for DPC (versican+). All data are shown as mean value ± 
SD. Asterisks mark significant (*p < 0.05; **p < 0.01) differences. 
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Figure 19. Expression of TGFβ2 and SCF in the HFM, RT-PCR analysis of SCF and TGFβ2 
 
A-B) Expression of TGFβ2 (as revealed by rhodamine immunostaining, red fluorescence) in the HFM (A) and 
in microdissected HF used as a positive control (B). C-D) Expression of SCF (as revealed by FITC immu-
nostaining, green fluorescence) in the HFM (C) and in microdissected HF (D). Original magnification, 100x for 
A, B, D; 250x for C. Nuclei were counterstained by DAPI (blue fluorescence). E-F) Reverse transcriptase PCR 
analysis of SCF (E) and TGFβ2 (F) (and β-actin, used as an internal control) mRNA expression in the HFM 
and in microdissected HF (used as positive controls). Lanes, 1 and 4, HF (positive control);2 and 5, reaction 
without template (negative control); 3 and 6, HFM. G) HFM were treated with 25 ng/ml TGFβ2, 10-6 M treti-
noin or 10 ng/ml Cyclosporin A (CsA) for 7 days and the expressions of TGFβ2- and SCF-specific mRNA were 
determined by RT-PCR. The amount of mRNA transcripts was then quantified by densitometry and the values 
obtained for TGFβ2 and SCF were normalized on the base of those for β-actin. Data of the treated groups, ob-
tained in 3 independent experiments, are expressed as mean ± SD values as a percentage of the matched 
control samples regarded as 100 % (line). Asterisks mark significant (*p < 0.05; **p < 0.01) differences.  
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7.2.3 Discussion 
 
Studies of the epithelial-mesenchymal interactions in the HF have been lim-
ited due to a lack of suitable in vitro screening systems that sufficiently mimic con-
ditions as they occur in human HF. So far, there are no available systems, which 
allow a higher-throughput screening of candidate hair drugs than can be obtained 
by using histoculture techniques or by the classical organ-culture of microdis-
sected, amputated human scalp HF in the anagen VI phase of the hair cycle 115,159. 
Even if this method, which is still the gold standard for in vitro analyses of human 
hair growth, is complemented by the addition of read-out parameters beyond hair 
shaft elongation 50,152,192, the very limited number of human HF available severely 
restricts the number of agents that can be screened. Also, while our understanding 
of epithelial-mesenchymal interactions in murine HF has recently progressed sub-
stantially173, our understanding of these interactions in human HF is still very rudi-
mentary. 
 
Some HF-like in vitro models derived from human follicular cells have been 
described 64,89,101,104,193. However, so far none of them are easily prepared in large 
amounts to allow high-throughput screening and to properly investigate epithelial-
mesenchymal interactions. The aim of this study was, therefore, to develop a 3D in 
vitro system that allows a more detailed examination of the basic molecular proc-
esses involved in HF growth and development with a robust reproducibility.  
 
In this study, a novel and very pragmatic organotypic assay, which imitates 
human HF-like epithelial-mesenchymal interactions and is prepared with compara-
tive ease has been described. Studying the expression of a number of different 
markers (e.g., proliferation, apoptosis, CK6 and versican expression),  it was 
shown that, under culture conditions with a serum-free, low-Ca medium, these 
HFM retain several essential characteristic for human scalp HF. 
 
The novel technique of the microsphere preparation using a gelling process 
of the matrix and cell mixture sustains high cell viability. The inclusion of Matrigel 
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(containing laminin and collagen IV) imitates the matrix environment of the follicu-
lar dermal papilla, namely that it more closely resembles that of basement mem-
branes, rather than of interfollicular dermis and enables to very closely mimic an 
extracellular matrix of the hair follicle mesenchyme. The low number of TUNEL 
positive cells in later phases of the culture with normalized LDH level suggests the 
optimal nutrient supply to the HFM also when the cell number has increased. Cul-
turing for more than 10 days is feasible when the number of cells, volume of ex-
tracellular matrix, and size of the HFM is increased during the preparation process. 
The system is highly reproducible, as thousands of microspheres were generated 
in past 10 experiments. 
 
The technique of the HFM preparation also allows easy cell migration within 
the microsphere compared to other spheroid systems. Nevertheless, although a 
mixture of isolated ORS and DPC with HF inductive potential175 was used in our 
experiments and the cell migration and matrix reorganization within the micro-
sphere was indeed observed, the formation of HF unit did not occur. This suggests 
that the interaction and signaling of the follicular cells with surrounding dermal    
micro-environment are crucial for morphogenesis and development of the HF. 
However, the main aim of this study was to develop a simplified hair follicle-like 3D 
in vitro system rather then to induce terminal HF formation. 
 
All hair growth-modulatory agents investigated altered apoptosis, prolifera-
tion, protein and gene expression in different cell populations within the HFM sys-
tem in a manner that suggests that HFM allow the standardized pre-clinical as-
sessment of test agents on relevant human hair growth markers under substan-
tially simplified in vitro conditions that approximate the in vivo situation. It was fur-
ther shown using a DNA microarray that HFM also offers a useful discovery tool 
for the identification of novel target genes for candidate hair drugs. Evidently, the 
HFM method still has limitations, especially in the rapid analysis of various read-
out parameters. These shortcomings will hopefully be overcome in the near future 
with the “automation” of the evaluation process by employing e.g. staining “robots”, 
automated image analyzer software packages, and high-content screening de-
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vices. Nevertheless, the novel assay system described is currently the only one 
that can claim to come at least close to overcoming the formidable remaining 
methodological challenges that have to be met before automation. 
 
In HFM, we were also able to identify several other markers important for 
the HF development and differentiation (e.g. CK14, β-catenin, IGF-I, IGF-I recep-
tor, alkaline phosphatase, data not shown). Due to the fact that there is no exclu-
sively ORS-specific marker available93,94, the use of CK6 immunostaining as a "HF 
type-keratinization marker for ORS" is a reasonable approach, even though it must 
be kept in mind that CK6 is also expressed by activated (e.g. wounded, inflamed 
or UV-irradiated) interfollicular epidermal keratinocytes and in the companion layer 
of HF94. The latter is unproblematic, since CK6 immunoreactivity originating from a 
companion layer-type epithelium within the microspheres would still reflect and 
confirm a HF-type keratinization pattern (the companion layer only exists within the 
HF epithelium). In addition, during our ORS isolation method and culture, no epi-
dermal components were present, and pure ORS keratinocyte cultures were gen-
erated (as confirmed by negative IRS markers). 
 
In conclusion, the presented data suggest that HFM represent a valuable 
system to study epithelial-mesenchymal interactions and their changes in re-
sponse to treatment with various candidate hair-drugs. HFM, therefore, do not only 
offer a novel and pragmatic basic screening tool, but also an instructive new ex-
perimental system for basic and applied pre-clinical hair research in the human 
system. 
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8 Conclusions from the study 
 
 
• Three new organotypic folliculoid systems (“layered sandwich”, “mixed 
sandwich”, microsphere system) for the exploration of molecular processes 
involved in HF growth were developed. 
 
• All newly developed systems meet all basic criteria for „folliculoid” organo-
typic systems that imitate human hair follicle epithelial-mesenchymal inter-
actions. 
 
• Outer root sheat keratinocytes proliferate in all systems, regardless of the 
calcium or serum content of the media, whereas the proliferation and apop-
tosis of dermal papilla cells, in all systems, strongly depends on the amount 
of serum and calcium in culture media. 
 
• The human folliculoid microsphere system (HFM), selected as the best op-
timized system, proved to be highly reproducible organotypic assay, which 
under culture conditions with a serum-free, low-Ca medium, retains several 
essential characteristic for human scalp HF. 
 
• HFM allow the standardized pre-clinical assessment of test agents on rele-
vant human hair growth markers under substantially simplified in vitro con-
ditions that approximate the in vivo situation. 
 
• HFM also offers a useful discovery tool for the identification of novel target 
genes for candidate hair drugs. 
 
• The HFM therefore offer a novel and pragmatic screening tool and an in-
structive new experimental system for basic and applied pre-clinical hair re-
search in the human system. 
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9 Summary   
 
The search for more effective drugs for the management of common hair 
growth disorders remains a top priority, both for clinical dermatology and the in-
dustry. Human hair growth can currently be studied in vitro by the use of organ-
cultured scalp hair follicles. However, simplified organotypic systems are needed 
for dissecting the underlying epithelial-mesenchymal interactions and as screening 
tools for candidate hair growth-modulatory agents. 
In this study, three novel organotypic human folliculoid assays for basic and 
applied hair research were developed. Two organotypic “sandwich” systems con-
sist of a pseudodermis (collagen I mixed with and contracted by human interfollicu-
lar dermal fibroblasts) on which one of two upper layers is placed: either a mixture 
of Matrigel™ and follicular dermal papilla fibroblasts (DPC), with outer root sheath 
keratinocytes (ORSK) layered on the top (“layered sandwich” system), or a mixture 
of Matrigel™, DPC and ORSK (“mixed sandwich” system). Third, the patented 
new technique generating human folliculoid microspheres (HFM), consisting of 
human DPC and ORSK within an extracellular matrix was established.  
Studying a number of different markers (e.g. proliferation, apoptosis, cy-
tokeratin-6, versican), it was shown that these folliculoid systems, cultured under 
well-defined conditions retain several essential epithelial-mesenchymal interac-
tions characteristic for human scalp hair follicle. Selected, recognized hair growth-
modulatory agents modulate these parameters in a manner that suggests that all 
developed organotypic systems allow the standardized pre-clinical assessment of 
test agents on relevant human hair growth markers under substantially simplified 
in vitro conditions that approximate the in vivo situation. Furthermore, by using 
immunohistochemistry, RT-PCR, and DNA microarray techniques it was shown 
that the folliculoid systems also offer a useful discovery tool for the identification of 
novel target genes and their products for candidate hair drugs. 
 Organotypic folliculoid systems thus represent an instructive new experi-
mental and screening tool for basic and applied hair research in the human sys-
tem. 
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A fully functional model of hair reconstitution remains elusive because of the 
complexity of cellular organization and the number of molecular interactions 
that must be approximated. In this issue, Havlickova et al. (2009) report a 
significant contribution to hair engineering with their human folliculoid 
microsphere assay. 
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